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Objective: Neurocysticerosis (NCC) is the leading cause of epilepsy in endemic areas. In 
the final stage of NCC, the viable intraparenchymal cysts die, either resolving completely 
or leaving calcified scars. In a proportion of patients they are accountable for the 
subsequent morbidity, mainly manifesting as epilepsy. These patients experience 
breakthrough seizures during their antiepileptic treatment and can later present with 
seizure relapse after their medication is withdrawn. This doctoral dissertation is intended 
to evaluate the proportion of calcification and its risk factors in patients with viable cysts 
who receive antiparasitic drugs (study 1) and the incidence and associated factors to 
seizure events in patients with already calcified NCC lesions during their antiepileptic 
treatment (study 2), and after the antiepileptic drug treatment is withdrawn (study 3).  
 
Methods: For the first study we evaluated the data of 220 adult patients with viable 
parenchymal NCC in a multilevel study from three previous clinical trials where patients 
received standard Albendazole (15 mg/kg/d), increased ABZ (22.5 mg/kg/d), or standard 
ABZ plus Praziquantel (PZQ, 50 mg/kg/d), and corticosteroids. Patients had MRI exams 
at baseline and at day 180 to assess cyst resolution and a CT scan at day 360 to assess 
calcification. For the second and third study we took advantage of a big cohort of patients 
with calcified NCC and neurological symptoms in Lima, Peru and developed a time-to-
event study. For study two we selected patients with diagnoses of epilepsy who were 
under AED treatment (n=210) and for study three we included those patients from the 
cohort of 210 patient in whom their antiepileptic drug (AED) was withdrawn (n=62). In 
both studies we followed the participants for breakthrough seizure (study two) or seizure 
relapse (study three) from the time of enrollment until event, loss to follow-up, 
administrative censoring (36 months of follow-up or until November 2017) or withdrawal 
of AED (in case of study 2). During the follow-up in both studies, patients had a clinical 
evaluation every three months and were contacted by the study team by phone every two 
weeks. All seizure events were classified according the ILAE guideline.  
 





Results: The first study included 147 patients with a total of 497 cysts, with an overall 
percentage of calcification at one year after antiparasitic treatment of 37.8% (188/497). In 
the multilevel model, we found in seven predictors of calcification, two at cyst level: 
cysts larger than 14 mm and cysts with surrounding edema, and five at patient level: 
patients with more than 2 years of seizures, having mild antibody responses on EITB, an 
increased dose of ABZ alone, receiving low dose of dexamethasone, and no early re-
treatment with antiparasitic drug. Study two involved 210 patients and 103 of those 
(49.1%) presented breakthrough seizure during the follow-up. In the time-to-event 
analysis the Kaplan-Meier method showed that only 36.0% remains free of epilepsy 
during the study time (36 months). The risk factors in the multivariate Cox analysis were 
having a seizure event in the year previous to the enrollment and a history of 10 or more 
seizure events. In the subsequent cohort (Study 3) 62 participants who withdrew AED 
were included, from them 17 (27.4%) presented with seizure relapses. The Kaplan-Meier 
estimator showed that the probability of being free of seizures after 3 years of AED 
withdrawal was 58.7%.  The Cox model showed that the main risk factors were having 
seizures in the last two years before AED withdrawal which was observed in 31 
participants; these participants had 9.2 times greater chances of having a seizure relapse. 
Because of that we perform a sub-analysis in this group and found that having a history 
of 10 or more seizures before AED withdrawal and a history of partial seizures with 
generalization or generalized seizures had a higher risk of having a seizure relapse, but 
without statistical significance. 
 
Conclusions: Residual calcified lesions after antiparasitic treatment in NCC represent 
less than half of cases and may be a preventable outcome. Some patients who present 
with remaining calcified scars developed breakthrough seizures under AED treatment and 
their management should be individualized.  Finally, withdrawal of antiepileptic 
treatment should only be considered after at least two years since last seizure event.  
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1. INTRODUCTION AND REVIEW OF THE LITERATURE 
 
1.1 INTRODUCTION  
 
Neurocysticercosis (NCC), defined as an infection of the central nervous system 
by the larval stage of the pork tapeworm Taenia solium, remains as a major challenge in 
public health mainly due to associated secondary epilepsy.
1-3
 It has been consistently 
demonstrated that NCC is the single most important risk factor for acquired epilepsy in 
poor regions, and most likely in the world, considering that 80% of the disease burden 
caused by epilepsy is located in developing countries.
4
 In endemic countries, cases of 
NCC are frequently diagnosed in hospitalized patients with epilepsy. A consistent 
association between NCC and seizures has also been shown in most population studies, 
where around 30% of all seizure cases are attributable to NCC.
5-8
 NCC is also 
increasingly diagnosed in industrialized countries due to immigration from endemic 
zones, with approximately 2,000 new cases per year diagnosed in the US only.
9-11
 
Financially, during a 10-year period (2003-2012), NCC was responsible for more than 
US $908 million in US hospitals, and hospitalizations and associated charges for NCC 




T. solium larvae establish in the brain parenchyma as viable cysts. As part of their 
natural life cycle and as an outcome of antiparasitic treatment, these cysts degenerate, 
either resolving or leaving a small calcified lesion in the brain parenchyma.
13
 Brain 
calcifications are commonly found in endemic areas for cysticercosis. In the general 
population, the proportion of asymptomatic individuals with calcified NCC ranges from 
5% to 25%.
14-18
  Cerebral calcifications can persist in the host’s brain for many years, and 
in endemic areas these calcifications have been associated with seizures in population-
based studies. In cross-sectional studies, the prevalence of NCC findings, mostly calcified 





lesions, ranges from 20% to 54%.
6-8
 In hospital-based studies, NCC also represents the 
primary cause of secondary epilepsy in endemic areas. 
6, 19-22
   
 
Although calcified NCC has a major role in seizure burden, the causal factors 
involved in the calcification process and the physiopathology of epileptic seizures in 
patients with calcified lesions are still inadequately understood.
23
 The proportion of 
viable and degenerating cysts that result in calcified scars ranges from 10% to 60% and 
use of antiparasitic treatment seems to leave more calcified scars compared with only 
symptomatic treatment or placebo.
24-26
 However, the factors or mechanisms involved in 
the calcification process have not been elucidated. It is still unknown why some cysts 




The incidence of seizure relapse in patients with calcified NCC has been 
inadequately studied. Our research group reported an incidence of 35.6 per 100 person-
year, but due to a limited sample size it was not possible to explore the risk factors 
associated with seizure relapse. Moreover, this study involved patients with only a single 
event, thus the diagnosis of epilepsy was not clearly established.
28
 Patients with epilepsy 
and calcified NCC typically remain under antiepileptic treatment for several years. After 
a period of two or more years without seizures, the antiepileptic drug is gradually 
withdrawn. A percentage of these patients will experience seizure relapse. Incidence of 
seizures and its risk factors have not been properly studied and very few studies report 
the relapse rate in this kind of patient. We have found only three publications which 
report a very high rate of seizure relapse of above 80%. 
29-31
 However, these studies 
present some limitations, such as few patients (30 or less) and a short follow-up period 
(12 months or less).  
 
This thesis research includes three separate studies. The first study explores risk 
factors associated with calcification in patients with viable cysticercosis who have 
received antiparasitic treatment. The second study evaluates risk factors for breakthrough 
seizure in patients with calcified NCC under antiepileptic treatment. Lastly, the third 





study evaluates risk factors for new seizures events in patients in whom the antiepileptic 
treatment has been withdrawn.  
  
1.2 NEUROCYSTICERCOSIS  
 
1.2.1 Life cycle  
 
Taenia solium is one of many cestode species that can infect humans and belongs 
to the phylum Platyhelminthes, class Cestoidea, order Cyclophyllidea, family Taenidae.
32
 
T. solium has a complex two-host life cycle. Humans are the definitive host and harbor 
the adult intestinal tapeworm, whereas both humans and pigs act as intermediate hosts by 
harboring the larvae or cysticerci. Other mammals can act as a definitive or intermediate 
host, but have minimal relevance for clinical disease or parasite transmission. Humans 
are infected through incidental ingestion of Taenia eggs in fecal-oral contamination 
(Figure 1.6.1). The embryos are liberated from the eggs, penetrate the intestinal wall 
mucosa, access the bloodstream, and are distributed throughout the body.  Once they 
reach a small terminal vessel, the embryos establish and evolve into metacestodes (post-
oncospheral stage) and encyst to form larval vesicles or cysticerci, reaching their 
definitive size in two to three months.
33
 Outside the nervous system, cysticercosis causes 
few or no symptoms and the cysts are usually identified and destroyed by the host's 
immune response. Clinical symptoms predominantly result from involvement of the eyes 
or the central nervous system (CNS). 
34
. According to their location in the CNS, we can 
identify several types of NCC, thus, patients can have one or mixed presentations of this 
disease, such as intraparenchymal, intraventricular, subarachnoidal, retinal, medular, and 
also spinal cyst. In this study we will only evaluate intraparenchymal cysticercosis which 
by far is the most frequent cerebral presentation.  
 
1.2.2 Intraparenchymal Cyst Stages   
 
Viable cysts are typically round or oval-shaped vesicles of approximately 1 to 2 
cm, with a translucent membrane through which the invaginated scolex is visible as a 





small nodule. The vesicular wall has a festooned appearance and is composed of three 
layers; the cuticular mantle, an external eosinophilic layer, a middle cellular layer formed 
by a pseudo-epithelial structure, and an inner layer composed of circular muscle and 
reticular fibers.
35
 The number of cysts is variable and they are most frequently located in 
the brain and muscles.  The vesicular content is primarily composed of water, but it also 
includes calcium, glycoproteins, cholinesterase, and coproporphyrin, components that 
confer the fluid’s antigenic properties.
3
 Vesicles vary in content according to their 
evolutionary stage.  After an undefined length of time, due to antiparasitic treatment or as 
consequence of their natural development, cyst degeneration begins mainly as a result of 
the host’s immunological reaction. The vesicular fluid becomes opaque and dense, while 
the cyst's edges become irregular and shrink.  The calcification process follows, usually 
starting in the cephalic portion of the parasite and progressing to the vesicular wall.  A 
round, hard, whitish, and calcareous nodule forms as a residual calcification. In endemic 
areas, radiographic images of calcifications are considered highly suggestive of NCC. 
13
 
Four distinct stages have been clearly identified for intraparenchymal cysticerci.
36
 
Changes in the surrounding brain tissues that are directly related to these stages have 
been observed. These changes have been clearly presented by Del Brutto and 




1.2.3 Radiological findings  
 
The four stages can be identified by neuroimaging; viable cysts without 
inflammation (vesicular stage) and with inflammation (colloidal stage), degenerating 
cysts (“enhancing lesions”, granular stage), and calcified cysts (calcified stage). These 
stages will be defined for this study according to their appearance on neuroimaging, by 




Viable cysts: Viable cysts are include in the vesicular and colloidal stages. These contain 
a parasitic vesicle with discernible liquid content in pre-contrast imaging series and may 
have associated signs of inflammation (perilesional edema and contrast enhancement) or 
not. Cysticercal cysts are hypodense with a thin smooth wall, and an interior central or 





eccentric density. The scolex is occasionally identifiable. Although cysts unrecognized by 
the host do not have significant enhancement or edema, those with enhancement and/or 
edema that are hypodense on T1 and FLAIR MRI techniques are considered viable. 
 
Enhancing lesion: Degenerating cyst whose liquid content is no longer visible on pre- 
contrast CT scan or MRI images. 
 
Calcification: Nodular images of calcium density on CT or MRI images. Calicified cysts 
are  more readily detectable on CT rather than MRI. 
 
 
1.2.4 Diagnosis of NCC 
 
Standard methods to diagnose NCC involve neuroimaging techniques, either 
computed tomography (CT) or magnetic resonance imaging (MRI).
34, 37
 There are no 
studies to evaluate the real sensitivity and specificity of CT or MRI scan for viable 
intraparenchymal NCC. For viable cysts MRI has a better performance than CT scan, 
however CT sensitivity is good for medium or large cysts.
39-43
 Also, in granulomas due to 
NCC, MRI has a better performance than CT scan, however in this scenario, use of a 
contrast substance, such as gadolinium, improves significantly the sensitivity of both 
techniques.
40, 44-47
. On the other hand, CT scan is the test of choice for calcified lesions 
given the enhancement of the calcium signal.
39-41, 43, 48-51
   
 
In general, MRI is more accurate than CT for viable and degenerating cysts, 
providing the best evaluation of the degree of infestation, location, size, and evolutionary 
stage of the parasite.  Perilesional edema and degenerative changes of the parasite are 
easier to detect on MRI, as are small cysts, cysts located in the ventricles, and racemose 
vesicles at the level of the posterior fossae and basal cisterns.
37, 52
 A CT scan, however, is 
more sensitive for the detection of calcifications, which are the overwhelmingly 









Serology using electroimmunotransfer blot (EITB Western Blot) technique which 
uses partially purified (lentil-lectin) glycoproteins as the antigenic parasite extracts 
(LLGP) provides specific confirmation of the diagnosis, with 100% specificity.
54, 55
 The 
sensitivity of immunostained Western blot in cases with viable parasites is estimated to 
be over 95%, although it is somewhat lower (50% to 60%) in patients with a single cyst 
or a single degenerating parasite. Patients with calcified NCC may be seronegative.
56-58
 
Other techniques to detect serum antibodies, such as ELISA, have lower performance and 
cross reaction with antigens from other cestodes.
59, 60
  Detection of circulating antigens 
using ELISA has lower sensitivity and specificity than immunostained Western blot. 
ELISA, however, seems promising as a tool to monitor the post-treatment evolution of 
patients with subarachnoid disease.
61-64
 Neuroimaging and serological tests (mainly EITB 
and Western blot) are two key tools to for diagnosis; however other approaches may be 
considered to achieve diagnosis. Thus in this thesis, we will follow the diagnostic criteria 






1.2.5 Treatment of Neurocysticercosis 
 
Up to 1978, therapeutic options for NCC were restricted to surgery for cyst 
excision, colocation of ventricular-peritoneal shunts, or steroids to decrease cyst-
associated inflammation. The discovery in Mexico that PZQ was effective for NCC in 
the mid-1980s provided the first effective specific drug.67, 68 Later, ABZ was studied as a 
cheaper and more effective agent.
69, 70
  The success of antiparasitic agents in 
neurocysticercosis was apparent: viable brain cysts disappeared soon after treatment and 
initial retrospective series showed that treated patients had much lower rates of seizure 
relapse.
71, 72
 However, some claimed that because symptoms only appear at the time of 
the cyst death and the associated host immune response to the released parasite antigens, 
it is counter indicated to hasten the natural inflammation by using parasiticidal drugs.
73, 74
 
The discordance between these two positions led to a discussion in the literature. The 
main argument was whether antiparasitic treatment or natural involution of the parasite 





will lead to less scarring and brain damage and thus a better prognosis in terms of the 
evolution of the seizure disorder and epilepsy. Unfortunately, some important aspects 
have been overlooked.  First, there are subgroups of NCC patients that not only benefit 
from antiparasitic therapy but can progress and even die if not treated, like those with 
Subarachnoid neurocysticercosis (SANCC).
26, 75, 76
 Similarly, complications in the 
treatment of NCC with antiparasitic drugs may be frequent, but severe complications are 
unusual.  
 
Antiparasitic treatment has shown important usefulness in orbital, medullary, or 
intraspinal cysticercosis. A simple summary would be that antiparasitic agents effectively 
destroy the cysticerci in the human brain at the cost of acute inflammation. In addition, 
combined antiparasitic therapy is more effective in killing parasites than 
monotherapy.
25,77
  Whether this is the most beneficial option for intraparenchymal 
cysticercosis in the long-term should be demonstrated, but in any case, the risks 
associated with this treatment are small. Additionally, it is published that increased doses 
and longer course of corticosteroid treatment can decrease symptoms, including seizures, 




In contrast to parenchymal NCC, there is wide consensus that extraparenchymal 
forms lead to progressive disease and should be aggressively managed.
75, 76, 79
 Critically, 
there have been no controlled studies to establish optimal therapy. Treatment of SANCC 
is currently based on long (one-month) courses of ABZ and ventricular-peritoneal 
shunting when necessary.  Efficacy of the first one-month course of ABZ therapy for 
SANCC is less than 40%.
80
 A recent American guideline has been published, and its 






1.3 NEUROCYSTICERCOSIS AND CALCIFIED LESIONS  
 
In some cases, the last stage in the degenerating process of brain cysts is 
calcification in which the parasite remnants appear as a solid calcified nodule.  In 1982, 





Grau and collaborators presented strong evidence favoring the hypothesis that the 
calcification process of cysticerci cysts is similar to that observed in other ectopic 
calcification, where the transformation of amorphous calcium generates hydroxyapatite 
and whitlockite.
82
 They analyzed calcified lesions from 19 autopsied human brains, 
describing the appearance of calcified cysticerci as irregular shaped stones. Compared 
with viable cysts, calcified lesions had significantly more calcium and phosphorus, 
mainly amorphous calcium phosphate with small amounts of hydroxyapatite and 
whitlockite. It also has been demonstrated that calcareous corpuscles contained only 
calcium carbonate. In addition, they identified organic components in hyaline and 
calcifications including proteins corresponding to extracellular fibers (approximately 30 
to 40% of the organic material), carbohydrates represented by glucose, and cholesterol. 
Thus, their study argues against the idea that the calcareous corpuscles play an important 
role as a nucleation center of calcification. Other findings include that initial calcium 
deposits occur in structures other that the scolex and that calcification is also observed in 
racemose cysts that do not contain a scolex.  
 
In two reports, the histopathological findings of surgically-removed calcified 
nodules in patients with perilesional edema and seizures also show organic components 
inside the calcified nodules. The calcified nodules were shown to be composed of 
collagen and degenerating cyst structures including the scolex, suckers, and calcareous 
corpuscle. One of these reports described the presence of amorphous calcifications, most 




Calcified lesions are no longer considered “inert nodules”. Initially, Nash and 
collaborators and then other authors
85-88
 hypothesized that calcified lesions can undergo 
intermittent morphological changes due to bone remodeling or other mechanisms. These 
processes could theoretically expose parasitic antigenic material to the immune system 
causing a transitory inflammatory response and edema that could be the causal 
mechanism for seizures, headaches or other neurological symptoms. Additional evidence 
to support this theory was exposed by Zurabian et al. (2005) who reported the presence of 
a protein band of ~260 kDa at Western blot assay associated with the calcareous 










The morphologic change from degenerating cyst (granuloma) to calcified lesion 
can occur over months to years. In some patients, and for reasons not well understood, 
this process does not progress, resulting in reduced calcification or absence of 
calcification. In individuals with a single degenerating lesion, the rate of residual 
calcification at one year ranges between 20% and 30% and antiparasitic treatment seems 





Sharma and collaborators published a cohort study in which 78 patients with 
solitary granuloma and new diagnosis of epilepsy were followed for 6 months. Brain CT 
scans done at month six showed residual calcifications in 21 (27%) and complete 
resolution in 57 (63%).
96
 The proportion of calcifications resulting after antiparasitic 
treatment of viable cysts varies from 10% to 60%, and unlike single granulomas, in 
viable brain cysts the use of antiparasitic drugs appears to be associated with a higher 
proportion of residual calcifications.
24-26
 However, risk factors for subsequent 
calcification have not been appropriately studied. 
 
  






1.4 NEUROCYSTICERCOSIS AND EPILEPSY  
 
1.4.1 Epilepsy  
 
Introduction. Epilepsy is one of the most common serious neurological 
conditions that affects more than 70 million people worldwide and is characterized by an 
enduring predisposition to produce spontaneous epileptic seizures
97
 This disease has 
several causes, and recently the International League Against Epilepsy (ILAE) has 
divided it into six categories: genetic, structural, metabolic, infectious, immune, and 
unknown.
98
  Among the infectious causes, parasitic infections, including cysticercosis, is 
one of the most common preventable factors for epilepsy around the world.
99
   
 
Epilepsy and Seizure Classification. The first classification of seizures and 
epilepsy was done by Gastaut in 1969.
100
 After the ILAE proposed classification of 
seizures in 1981,
101
 where seizures were dichotomized to partial (restricted to a system of 
neurons and limited to part of one cerebral hemisphere) or generalized (involving both 
hemispheres). Then, in 1985, the ILAE proposed a revised classification of epilepsy 
102
 
introducing a new epilepsy classification of idiopathic or symptomatic. In 1989
103
 the 
classification of cryptogenic epilepsy was added.  Fisher et al.,
104
 in 2005 defined “An 
epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain. Epilepsy is a disorder of the 
brain characterized by an enduring predisposition to generate epileptic seizures and by 
the neurobiologic, cognitive, psychological, and social consequences of this condition. 
The definition of epilepsy requires the occurrence of at least one epileptic seizure”, it was 
practically applied as having two unprovoked seizure events 24 hours apart.  
 
In 2010, the term partial seizure was replaced by focal seizure by a new revision 
by the ILAE,
105
 and most importantly, generalized and focal were redefined for “seizures 
as occurring in and rapidly engaging bilaterally distributed networks (generalized) and 





within networks limited to one hemisphere and either discretely localized or more widely 
distributed (focal)”.  After that, in 2014 the ILAE task force published a new practical 
clinical definition of epilepsy that defined epilepsy as a disease that fulfill any of the 
following conditions: (1) At least two unprovoked (or reflex) seizures occurring more 
than 24 hours apart; (2) one unprovoked (or reflex) seizure and a probability of at least 
60% of having further seizures occurring over the next 10 years; (3) diagnosis of an 
epilepsy syndrome.
97
 Finally, in 2017 the ILAE published an operational classification 
where the onset of seizure takes the main role, and classify the epileptic seizure as focal, 
generalized or unknown onset.
106
 For practical reasons, for the analysis in our studies, we 
classified the epileptic seizure into two categories according the extent of brain 
involvement:  focal seizures and generalized seizures (which includes focal onset seizures 
with bilateral generalization and generalized onset seizures).   
 
1.4.2 Prevalence and semiology of Epilepsy due to NCC 
 
Seizures are the most common form of clinical presentation of parenchymal NCC 
and often represent the primary manifestation of this parasitic disease. The association 
between cysticercosis, recurrent seizures, and epilepsy has been consistently 
demonstrated. Firstly in case series descriptions,
19, 107
 and more recently in field studies 
using CT in the general population.
18,53,108,109
 While the percentage of NCC patients 
presenting with seizures varies considerably, most series have shown that epilepsy may 
occur in up to 80% of patients. In a systematic review, neuroimaging evidence 
compatible with NCC among people with epilepsy was similar in clinical versus 
community studies (32% versus 25%, respectively). Also, the proportion of NCC was 
similar when adults versus children with epilepsy were compared (28% vs 25%, 
respectively).
8
 Another recent systematic and meta-analysis evaluated publications from 
23 countries with a total of 37 studies. Association between NCC and epilepsy was 
significant, and odds ratios ranged from 0.2 to 25.4 reported by different studies, with a 
common odds ratio of 2.7 (95% CI 2.1-3.6, p <0.001). In these studies, NCC can be the 









Most cases of NCC-related epilepsy occur in rural and semi-rural areas of 
developing countries. In these regions, neuroimaging studies have shown that 
parenchymal brain calcified NCC is the most common form of the disease.
18, 109
 Since 
symptomatic patients seeking medical care represent only a small proportion of 
individuals with NCC, findings from hospital-based studies cannot be extrapolated to the 
entire population. In a hospital setting, most patients with NCC present with seizures. 
Moreover, the most common findings in neuroimages in these cases are viable or 
degenerating cysts.
71
 At the population level, most infected individuals (as demonstrated 
by serology or brain CT) are asymptomatic.
14, 17, 18, 108, 110
 Of those with NCC-associated 
seizures in community settings, the vast majority have calcified disease, and half of them 
are already seronegative.
18, 53
 However, the literature is inconsistent on whether focal or 
generalized seizures predominate among NCC patients. Most authors concur that there is 
not an exact correlation between the number and location of cysticerci with clinical 
characteristics of the associated seizures.
71, 111
 In some series, there is predominance of 
focal seizures with or without secondary generalization,
111-114
 and in others, generalized 
seizures are the most common form of presentation of the disease
71, 115, 116
 Also in 







Clinical manifestations of NCC are related to several pathogenetic mechanisms 
such as immuno-regulation (which allows the eggs to reach the cystic stage and to live 
several years in immune equilibrium with the host), inflammation (as an immunological 
response to foreign antigens from the parasite), granuloma formation and ectopic 
calcification, disruption of the brain blood barrier, and finally epileptogenesis. When 
cysts begin to degenerate, they provoke a variable inflammatory response that frequently 
results in the occurrence of one or more reactive seizures. This most likely reflects the 
loss of a state of immune equilibrium between the parasite and the host.
120
 Degenerating 
cysticerci eventually regress, but often seizures continue because of an exacerbation of 
the inflammation or by other mechanisms at any time during the process of degeneration 






. Notably, antiparasitic treatment of viable parenchymal brain cysts induces host 
inflammatory responses and may cause symptoms like headaches or seizures 
25, 122, 123
. 





Calcified lesions are also implicated in the genesis and/or maintenance of seizures 
and epilepsy. As previously noted, however, seizure semiology is not always concordant 
with the localization of the lesion.
23, 28, 124
 One hypothesis of epileptogenesis in NCC 
patients centers on disruption of the blood-brain barrier and associated inflammation. 
Host inflammation directed to degenerating cysts is associated with abnormal vascular 
permeability and neuronal dysfunction, resulting in increased cortical excitability and 
acute reactive seizures. However, it is unknown how these acute effects lead to the 
development of a chronic, focal or distant epileptic disorder. Possible mechanisms 
include progressive brain inflammation, reactive gliosis, cellular damage, and increased 
blood-brain barrier breakdown, which may contribute to inflammation by creating a 
positive feedback loop.
27,125
 These mechanisms, together with changes in brain 
excitability, might lead to a chronic epileptic state. So far, the precise epileptogenic 
mechanisms of NCC have not been elucidated and there is no proven clinical approach 
for the prevention of epilepsy in asymptomatic infected individuals.
126
   
 
1.4.4 Calcifications, gliosis and the role of hippocampal sclerosis 
 
As noted, residual calcified lesions are the most common cerebral finding of 
NCC. In patients who had viable cysts, calcified cysticercosis is the chronic condition to 
be faced after treatment. However, the importance of disease manifestations associated 
with calcified lesions has not been well characterized. In fact, this parasitic stage is still 
regularly referred to as “inactive NCC”, suggesting an end stage and/or a state of less 
clinical importance. It is agreed that even after a successful anti-parasitic treatment, the 










There is growing evidence implicating calcified cysticerci in the genesis and/or 
maintenance of seizures and epilepsy in endemic populations. Calcified cerebral lesions 
are a common CT finding in persons with seizures in endemic areas. Indeed, in 
community based studies, calcified scars are much more frequent than viable cysts and 
more prevalent in symptomatic compared to asymptomatic participants; symptoms in 
individuals with only calcified disease are associated in a sizable proportion of 
individuals with perilesional brain edema around one or more calcified lesions.
28, 84
 Also, 
seizure semiology is frequently concordant with the localization of the calcified 
lesion.
23,124
 In a study performed by our group, perilesional edema was present in one 
third of patients with only calcified lesions who presented with seizures.
84
 Another 
prospective cohort study in 110 patients with calcified NCC demonstrated an estimated 5-
year seizure incidence of 36%, and found peri-calcification edema in 50% of the patients 
with a recent seizure episode, compared to 8% asymptomatic matched controls.
28
 Thus, 
peri-calcification edema occurs frequently and is associated with episodic seizure activity 
in calcified NCC, suggesting a unique and possibly preventable cause of seizures in this 
population.  
 
In addition, it has been consistently reported that gliosis surrounding calcified 
lesions are related to refractory epilepsy. In one study, seizure recurrences were 
significantly higher in individuals with calcifications surrounded by gliosis than in those 
without.
128
 In another randomized controlled trial of individuals with a solitary 
cysticercus granuloma (SCG), it was found that, irrespective of AED therapy, that the 





Data from specialized epilepsy surgery centers in Latin America indicate that 
patients with NCC and refractory epilepsy often have seizures arising from hippocampal 
sclerosis and not necessarily from the calcified lesion itself. In most of these cases, a 
seizure-free state resulted after the surgical resection of the anterior temporal lobe, and 









In a recent cross-sectional population-based study, it has been demonstrated that 
calcified NCC is associated with hippocampal atrophy in older adults living in an 
endemic rural village.
16, 134
 Theoretically, calcified NCC may lead to hippocampal 
sclerosis (HS) by causing recurrent seizures or status epilepticus. Brain calcifications may 
undergo periodic morphological changes related to remodeling mechanisms,
23, 27, 121
 
exposing trapped proteins of the parasite to the immune system, resulting in 
inflammatory changes in the brain parenchyma and recurrent seizures, which can lead to 
hippocampal damage in the long term. The resulting HS may, in turn, exacerbate the 
seizure disorder. Alternatively, irrespective of the occurrence of seizures, calcified 
cysticerci can lead to hippocampal damage mediated by remote inflammatory 
mechanisms,
135
 as demonstrated in experimental studies.
136, 137
 Further research is 
required to elucidate the relationship among epilepsy calcification due to NCC and 
hippocampal sclerosis.  
 
1.4.5 Breakthrough Seizures  
 
A breakthrough seizure is defined as a new seizure event after a crisis-free time in 
patients under AED treatment. Some authors consider this time as 12 months, however 





1.4.5.1 Breakthrough Seizures in non-NCC patients  
 
Breakthrough seizures (BTS) have been reported in several studies. Kim and 
collaborators have shown that proportion of BTS at one year can reach 36%, 46% and 
50% after one, three and five years of starting AED. The significant risk factors for BTS 
were number of previous seizures (more than 3), presence of a neurological disorder, and 
an epileptic abnormal EEG.
140
 Beghi et al. reported the probability of BTS of 38%, 40% 
and 46% at one, two, and three years respectively. Moreover, the risk factors were the 
number of previous seizures, having mixed types of seizures, and identified etiologic 







 The proportions of BTS are similar to the above referred studies and other 
potential causes or triggers has been reported by the literature such as poor adherence to 
AED, concurrent inflammatory condition or infection, emotional stress, concomitant 
medication that lower the seizure threshold, sleep deprivation, diarrhea, metabolic events, 
flashing lights, etc.
139
     
 
1.4.5.2 Breakthrough Seizures in calcified NCC   
 
The incidence of seizure recurrence (breakthrough seizures) and their predictive 
factors in patients with calcified NCC and epilepsy under antiepileptic treatment has been 
poorly studied. Sharma et al.,
96
 published a report where 35 patients with newly 
diagnosed epilepsy and with a single calcification were followed up for 6 months. In this 
study, 12 (34.3%) patients presented with seizure recurrence and, in their unadjusted 
model, the predictors of recurrence were abnormal EEG findings, a family history of 
epilepsy, and serial seizures at onset. In the adjusted model none of these factors were 




Nash et al. reported a longitudinal study with 64 patients with calcified lesions. In 
this study we found a 5-year incidence of seizure relapses of 36%. However, this cohort 
is composed by 55% of people with epilepsy without AED treatment, and in this group 
the HR was 5 times higher compared to subjects without treatment. In the group under 
AED treatment the prognostic factors associated with risk of seizures were the number of 





In a recent publication, Singh and collaborators,
142
 studied a cohort of 54 PWE 
and single calcified lesions receiving AEDs who were followed-up for one year. This 
cohort presented a BTS incidence of 24% (13/54) and the associated factors were history 
of status epilepticus, perilesional edema, and visualization of scolex at baseline 
neuroimaging.  
  





1.4.6 Antiepileptic drug withdrawal and seizure relapse  
 
There is no consensus on a single and standardized AED withdrawal approach for 
patients with epilepsy and NCC. Indeed, the length of AED therapy has been mostly 
based on expert opinion and there are few systematic data supporting AED withdrawal in 
these cases. The rate of seizure recurrence as well as factors that increase the risk of 
relapses should be considered before AED withdrawal in these cases. These factors have 
been extensively studied in conditions other than NCC, and such evidence might provide 
some helpful clues when attempting AED withdrawal in NCC patients.  
 
1.4.7 General principles of AED withdrawal. 
  
In all forms of epilepsy, benefits from AEDs withdrawal are mostly related to 
avoiding side effects like cognitive impairment or potential teratogenic effects, improving 
quality of life, reduction of economic burden, reduction of stigma, and elimination of the 
potential for drug’s interactions.
143
 On the other hand, disadvantages related to AED 
withdrawal include increasing risk of relapses, as well as loss of driving license or loss of 
independence in activities with risk.
144
  The main outcome of AED withdrawal is having 
minimal or no seizure recurrence. Many studies of discontinuance of antiepileptic 
treatment have been reported by the literature showing variable rates of recurrence as 
shown in Table 1.7.4. In persons with epilepsy from causes other than NCC, several risk 
factors for seizure recurrence have been recognized, such as older age at seizure onset, 
duration of epilepsy, abnormal neurological examination or psychiatric findings, 
abnormal EEG findings, increased number of seizures during AED therapy or history of 
epileptic status, greater number of AED used during treatment, and failure in previous 
withdrawal attempts.
145
 Theoretically, all these factors may influence the rate of relapses 
after AED withdrawal in patients with epilepsy and NCC. 
 
Those reports are mostly retrospective, observational, and uncontrolled.
145, 146
 
Cumulative probability of seizure recurrence, reported by literature in adult population 





ranges from 15% to 32% at 1 year of follow-up after AED withdrawal
143, 147-149
 and from 




1.4.8 Seizure recurrence in NCC patients after AED withdrawal.  
 
Most studies specifically dealing with AED withdrawal in patients with epilepsy 
and NCC are retrospective, small, or non-controlled as shown in Table 1.7.5.
29, 30, 152-156
  
In a case series of 40 patients with NCC who had been free of seizures for two years, the 
observed relapse rate was 50% at one year of follow-up after AED suspension.
29
 In this 
series, residual calcification and history of both recurrent seizures and multiple viable 
cysts were important risk factors for seizure recurrence.  
 
A high rate of seizure relapse was reported by the same authors in a subsequent 
cohort of 30 patients with calcified NCC, 15 of whom received antiparasitic treatment (as 
they presented with viable cysts) and 15 who presented with spontaneously calcified 
cysticerci.
30
 Both groups had been free of seizures for two years, and were followed for 
twelve months after AED withdrawal. The rate of recurrence was similar in both groups, 
and 83% of them presented with recurrences within six months of AED discontinuation. 
Results of this study argued against previous unsupported assumptions that the use of 
cysticidal drugs leave a more profound scar in the brain parenchyma than when the 
parasites calcified spontaneously.
157
   
 
In a study conducted in India assessing risk factors associated with relapses after 
withdrawal in 73 patients with SCG, the presence of residual calcifications and not the 
length of AED therapy (six months versus two years) was associated with an increased 
risk of seizure recurrences.
155
 In another study from India, 81 subjects with epilepsy and 
SCG were randomly allocated to receive six or 12 months of AEDs and were followed 
for one year after AED therapy.
154
 Only 12% of patients showed relapses (in both groups) 
and all cases occurred during the first six months after AEDs withdrawal. Given that 
most of the relapsing cases in both groups were observed in patients with residual 





calcification, the authors concluded that individuals with persistent calcified lesion might 
need longer AED treatment. 
 
Three other studies in patients from India with SCG showed similar results. In one 
of them, 115 children were allocated to AED withdrawal after one or two years free of 
seizures.
153
 Rates of relapses were similar in both groups, but it was noticed that patients 
with both a residual calcification and abnormal EEG recordings had the greatest chance 
of seizure recurrences after AED withdrawal. In another series, AEDs were rapidly (2-12 
weeks) tapered after CT showed resolution of the SCG. Out of 185 patients, 28 had 
relapses; risk factors associated with relapses included the development of a residual 
calcification as well as history of more than one seizures or breakthrough seizures before 
achieving control.
90
 In a third study, including 206 individuals randomly allocated to 
receive one or two years of AED therapy and followed up to 18 months after withdrawal, 
it was observed that seizure recurrences in those left with a residual calcification were 









In viable parenchymal cysts, after interruption of the immunological equilibrium, 
we observed morphological change from granuloma to calcified lesion or complete 
clearance of the lesion. In single enhancing lesion the proportion of calcification has been 
reported in a range of 20% to 30%.
90-95
  In viable parenchymal cysts, the proportion of 
calcification after antihelmintic treatment range from 10% to 60%,
24-26
 however risk 
factors for calcification have not been studied. 
 
The incidence of seizure relapse in patients with calcified NCC and epilepsy has 
been inadequately studied. Our research group reported an incidence of 35.6 per 100 





person-year, but due to a limited sample size and the heterogeneity of the participants, it 
was not possible to explore the risk factors associated with seizure relapse adequately.
28
 
Patients with epilepsy and calcified NCC typically remain under antiepileptic treatment 
for several years and beside treatment, show a presence of breakthrough seizures.  
Largely based on expert opinions, after a period of two to three years without seizures, 
the antiepileptic drug is gradually withdrawn. However, some of these patients will 
experience seizure relapse. The relationships between the incidence of seizures, its risk 
factors of breakthrough seizure, and seizure relapse have not been properly studied.  
 
This dissertation reports on the findings of three studies that explore the 
pathological outcomes of NCC. The first study will explore risk factors associated with 
calcification in patients with viable cysticercosis who have received antiparasitic 
treatment. The second study will evaluate risk factors for breakthrough seizure in patients 
with calcified NCC who are under antiepileptic treatment. The third study will evaluate 




1.5.2 Study Aims  
 
Study 1: To estimate the incidence of calcification in patients with viable parenchymal 
cysticercosis after one year of antiparasitic treatment and to evaluate associated risk 
factors. 
 
Study 2: To evaluate the incidence rate, cumulative incidence and risk factors of seizure 
breakthrough in patients with epilepsy due to calcified NCC who are under antiepileptic 
drug therapy. 
 
Study 3: To evaluate the incidence rate, cumulative incidence and risk factors of seizure 
relapse in patients with epilepsy due to calcified NCC who had stopped their AED 
treatment.  






















Appearance of the parasite 




Translucent vesicular wall; transparent 
vesicular fluid; viable invaginated 
scolex 
Scarce inflammation reaction; formation 
of a collagen capsule around the parasite 
Colloidal 
stage 
Thick vesicular wall; turbid vesicular 
fluid; scolex showing signs of hyaline 
degeneration 
Intense inflammatory reaction that 
includes the parasite; thick collagen 
capsule around the parasite 
Granular 
stage 
Thick vesicular wall; degenerated 
scolex 




Transformation of the parasite in coarse 
calcified nodules 





Table 1.7.2. Differences of evolutive stages on CT and MRI (MRI FLAIR and T2 




MRI -FLAIR MRI-T2 Enhancement Edema 
Cyst without 
inflammation 
Hypodense Hypointense Hyperintense Not Not 
Cyst with 
inflammation 
Hypodense Hypointense Hyperintense Yes (perilesional) Usually 
Enhancing 
lesion 


























Table  1.7.4. Seizure relapse rate in patients after AED withdrawal in non-cisticercotic 
patients 
 








 Adults (n=79) 12 mo. 15%  >= 2y 
MRCADW (1991) 
147
 Adults(n= 883) 12 mo. 32% >= 2y 
MRCADW (1991) 
147
 Adults(n= 883) 24 mo. 41% >= 2y 
Berg (1994) 
148
 Meta-analysis 12 mo. 25% NS 
Berg (1994) 
148
 Meta-analysis 24 mo. 29% NS 
Specchio (2002) 
149
 A&Ch (n=225) 6 mo. 12% >= 2y 
Specchio (2002) 
149
 A&Ch (n=225) 12 mo. 26% >= 2y 
Specchio (2002) 
149
 A&Ch (n=225) 24 mo. 43% >= 2y 
Specchio (2002) 
149
 A&Ch (n=225) 36 mo. 49% >= 2y 
Specchio (2002) 
149
 A&Ch (n=225) 60 mo. 52% >= 2y 
Ricci (1999) 
158
 Adults (n=125) 6m 15% >1y 
Avoni (1995) 
159
 Adults (n=286 ) >3y 53% 2y – 6y 
Mastropaolo (1992) 
160
 A&Ch (n=191) NS NS NS 
Alvarez (1989) 
150
 Adults (n=50) 2y 30 % > 2y 
Alvarez (1989) 
150
 Adults (n=50) 3y 42 % > 2y 
Callaghan (1988) 
161
 A&Ch (n=92) 
2.1y (0.5-
5y) 
34% > 2y 
Overweg (1987) 
162
 Adults (n=62) > 2y 66% > 3y 
Pestre (1987) 
163
 Adults (n=272) NS 49% NS 
Juul-Jensen (1964) 
151
 Adults (n=200) 2y 35% 2y 
(*) Relapse after withdrawal or AED reduction, A&Ch: Adults and children, NS: Not specified 
 
























Del Brutto (1994) 29 
Adults 
(n=40) 





- Multiple cysts  
6-8 weeks 
Garg  (1998) 152 
A&Ch  
(n= 25) 
< 3 mo.  SEL  16% NS NS Abruptly 
Singhi (2003) 153 
Children 
(n=55) 
>12mo. SEL 4.5% 1y 
- Residual 
calcification 
- Abnormal EEG 
 8-12 weeks 
Singhi (2003) 153 
Children 
(n=51) 
>12mo. SEL 5.8% 2y 
- Residual 
calcification 
- Abnormal EEG 
 8-12 weeks 
Del Brutto (1996) 30 
Adults 
(n=30) 
12 mo. Calcified 83.3% 2y 
- Sex, age. 
- Type and number 
of seizures 
- Number of 
calcifications 









- More than one 
seizure 
2-12 weeks 
Del Brutto (1997) 41 
Children 
(n=13) 












Thussu (2002) 155 
A&Ch  
(n=47) 




Thussu (2002) 155 
A&Ch  
(n=26) 




Verma (2006)  156 
A&Ch  
(n=65) 




Verma (2006)  156 
A&Ch  
(n=62) 




F-U Time: Follow-up time, SEL: Single enhancing lesion, SCCG: Solitary cerebral 
cysticercus granuloma, A&Ch: Adults and children, NS: Not specified  





1.8 NOTES  
 
This introduction has been partially used to publish a review paper. 
 
 Bustos JA, García HH, Del Brutto OH. Antiepileptic drug therapy and 
recommendations for withdrawal in patients with seizures and epilepsy due to 
neurocysticercosis. Expert Rev Neurother. 2016 Sep;16(9):1079-85. doi: 
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2.1 ABSTRACT  
 
2.1.1 Introduction  
Neurocysticercosis (NCC) is a major cause of acquired epilepsy in endemic areas. 
Along its natural course of evolution or as an effect of antiparasitic treatment, the host´s 
inflammatory response leads to cyst degeneration, which in some cases ends as a 
calcified scar. This study assessed the proportion of residual calcification at one year in 
parenchymal brain cysts that resolved after antiparasitic treatment, and the risk factors 
associated with their calcification.  
 
2.1.2 Methods 
We evaluated data from 220 adult patients with viable parenchymal NCC from 
three previous randomized clinical trials where patients received standard albendazole 
(ABZ) (15mg/kg/d), increased ABZ (22.5mg/kg/d), standard ABZ plus praziquantel 
(PZQ 50mg/kg/d) or placebo (PCB), and concomitant anti-inflammatory therapy with 
dexamethasone (DXM).   Patients had MRI exams at baseline and at day 180 to assess 
cyst resolution and a CT scan at day 360 to assess residual calcifications.   We selected 
cases with complete follow up (MRI at day 180 and CT at day 360).  Multilevel Poisson 
regression model with random intercepts adjusted by covariates at the patient and cyst 
levels was used to estimate risk ratios of calcification.  
 
2.1.3 Results 
A total of 497 cysts in 147 patients were evaluated, with an overall 37.8% of 
calcification at one year after treatment of (188/497). Positive predictors for residual 
calcification at the cyst level were cysts larger than 14 mm (RR 1.34, p=0.035), and cysts 
with surrounding edema at baseline (RR 1.39 p=0.023). At the patient level, a history of 
more than 24 months with seizures (RR: 1.25; p=0.003), mild antibody response (less 
than four antibody bands on western blot, RR: 1.14; p=0.020), increased dose of ABZ 
(RR: 1.26; p<0.001), lower dose of DXM (RR: 1.36; p=0.037), no early re-treatment in 
patients with incomplete resolution of cysts (RR: 1.45 p=0.012) or complete cure (RR: 
1.48 p<0.001]). 







Approximately 40% of parenchymal NCC cyst resulted in a residual calcification after 
antiparasitic treatment. Some risk factors are modifiable (steroid dose, antiparasitic 
regime, early re-treatment) and may contribute to decrease or avoid calcification, 
potentially decreasing the risk for seizure relapses. 
  





2.2 INTRODUCTION  
Neurocysticercosis (NCC), a parasitic infection of the human central nervous 
system (CNS) by larval cysticerci of the cestode Taenia solium, is as a global public 
health problem and important source of neurologic disease. The presence of the parasite 
in the brain, and the associated host inflammatory response, causes seizures, intracranial 
hypertension, and other neurological symptoms.
19, 164
  The parasite initially establishes as 
a viable cyst that is in immunologic equilibrium and induces minimal or no inflammation. 
Over time, the cyst loses its integrity, either because of the natural progression of the 
infection or in response to antiparasitic chemotherapy. Parasite antigens become exposed 
to the immune system resulting in a host inflammatory response that frequently causes 
neurological symptoms.
13
 The cyst degenerates into a granuloma as the infection is 
cleared, and in some instances, the degeneration process results in a calcified lesion that 




Calcified lesions are not inert or inactive nodules as previously believed.
27, 84
 It 
has been consistently demonstrated that calcified cysticerci can be permanent foci of 
seizures and other neurological symptoms, although the pathogenic mechanisms are not 
well understood.
23, 51, 146, 165, 166
   Nash et al. 
85
 and subsequently others
85-89, 167
 suggest the 
hypothesis that calcified lesions undergo morphological changes similar to bone 
remodeling intermittently exposing parasitic antigenic material to the immune system, 
and the antigen exposure triggers an inflammatory response that leads to seizures, 
headaches, or other neurological symptoms. It has also been proposed that direct contact 
of calcium with cerebral tissues can have a toxic effect resulting in seizure activity.
168
 
Finally, the process of perilesional gliosis, starting even when cysts are viable, could 
result in chronic brain tissue damage and persistent foci for seizure activity.
88, 129, 169, 170
 
 
The morphologic change from granuloma into a calcified lesion can take months 
to years. In some patients, and for reasons still not well elucidated, this process is altered 
or even halted, resulting in little or no residual calcification.
24-26
 In individuals with a 
single degenerating cyst, the rate of residual calcification at 1 year ranges between 20% 
and 30%,
90-95
 where antiparasitic treatment seems to reduce the likelihood of developing 





a subsequent calcified lesion.
95, 171
 In individuals with viable cysts, the proportion of 
calcifications resulting after antiparasitic treatment has not been systematically assessed, 
although estimates range from 10% to 60%. Risk factors for subsequent calcification 
remain unknown.
24, 25
 This study estimated the incidence of calcification in patients with 
viable parenchymal cysticercosis one year after antiparasitic treatment and identified 
factors associated with a higher risk for calcification. 
  






2.3 MATERIAL AND METHODS 
 
2.3.1 Study design. This is a retrospective cohort study using data previously collected in 
three clinical trials on antiparasitic treatment for viable parenchymal NCC performed by 




2.3.2 Study outcomes. The main outcome was evaluated at the level of the cyst rather 
than the participant. For each cyst that resolved after antiparasitic treatment, the presence 
or absence of a calcified lesion in the location of the original cyst 12 months after 
initiation of antiparasitic treatment was defined by topographic identification of each 
lesion. It was assessed using MRI at baseline and at month 6 and by CT scan at month 12 
(Figure 2.7.1). 
 
2.3.3 Study population and selection criteria. We identified eligible individuals from a 
total population of 220 participants in three parent clinical trials. The first trial compared 
two regimes of dexamethasone (either 6 mg/d for 14 days [n=32], or 8 mg/d for 28 days 
with a 2-week taper [n=32]) in patients receiving standard doses of albendazole (ABZ) 
(15 mg/kg/d for 14 days).
78
 The other two parent trials assessed the pharmacokinetics, 
safety, and efficacy of combined ABZ plus praziquantel (PZQ) treatment. In the second 
trial, patients treated with ABZ at 15 mg/kg/d for 10 days were randomized to also 
receive either PZQ (n=16) or placebo (n=16).
172, 173
 In the third trial, patients were 
randomized to receive 10 days of either standard ABZ treatment plus PZQ (n=41), 





All participants in the trials were between 16-65 years-old, had epilepsy, and had 
NCC with 20 or fewer viable parenchymal cysts at baseline based on brain CT and MRI 
scans. Detailed eligibility criteria for each trial are described in the original publications. 
77, 78, 172
 Trial participants underwent an MRI scan 6-months after treatment initiation to 





assess cyst resolution, and a CT scan at 12-months to identify residual calcifications 
(typically seen as well-defined hyperdense rounded, nodular or punctuate solid lesions). 
Trial participants were eligible for this cohort study if they completed both the MRI and 
CT follow up evaluations, and if at least one of the baseline viable cysts resolved with 
antiparasitic treatment (Study flowchart, Figure 2.7.2).  
 
2.3.4 Data source. Anonymized demographic, clinical and radiological information 
collected in the original trials was collected for this study. Data included participant age 
(years), sex, time-period between first seizure and enrollment (months), number of anti-T. 
solium antibody bands reactive on enzyme-linked immunoelectrotransfer blot (EITB 
western blot, 1 to 7 bands), previous antiparasitic treatment, previous use of antiepileptic 
drugs, antiparasitic treatment regimen received in the trial (standard ABZ, increased 
ABZ, or combined ABZ plus PZQ), length of antiparasitic treatment (10 versus 14 days), 
initial dose of dexamethasone (mg/day), length of dexamethasone treatment (10-12 days 
versus 28 days). MRIs were performed on 1.5T or 3T MRI machines using T1, T2 and 
Flair protocols (before and after contrast agent injection). Non-contrasted CT scan were 
performed at baseline and 12 months after in majority of the cases in a Siemens Somatom 
IV helical scanner.   
 
Radiologic data from MRI and CT scans included the number and topographic 
location of the cysts and calcified lesions as well as cyst size (using the greatest diameter 
in millimeters), cyst content (clear or turbid), and the presence of pericystic edema 
(defined as hyper-intense signal on fluid-attenuation inverse recovery (FLAIR) or T2 
MRI sequences). Cyst resolution at month 6 was defined as absence of discernible 
hyperintense content on T2 MRI sequences. In addition, study charts were revised to find 
out whether patients had received anti-parasitic re-treatment between their 6-month MRI 
scan follow up and their 12-month CT scan assessment.  For the current study, two NCC 
experts re-evaluated all MRI and CT scans to verify the accuracy of recorded outcome 
data. Any potential discrepancies were resolved by consensus.  
 





2.3.5 Statistical analysis. Main covariates were described using summary statistics 
(mean ± standard deviation or median with ranges for numerical variables, and 
percentages for categorical variables), and compared initially between included and 
excluded participants to rule out selection biases. The overall percentage of residual 
calcification in cysts that resolved after antiparasitic treatment was calculated.  
 
Due to the multi two-level nature of the data, we used a multilevel Poisson regression 
with random effects for individual intercepts to estimate risk ratios (RR) of calcification 
with 95% confidence intervals using covariates at the cyst and at the individual level. 
Bivariate models were initially performed for each covariate of interest. Subsequently, 
we performed a multivariate model including all covariates at the cyst level using a 
stepwise approach with backward selection algorithm retaining covariates with p<0.05 
derived from Wald test. A second model was then performed with covariates selected in 
the first model, and including all covariates at the patient level using a similar stepwise 
approach. All models were estimated using mean-variance adaptive Gauss-Hermite 
quadrature with seven integration points for each level of random effects. Standard errors 
were estimated using cluster-robust variance estimates to account for correlation within 
each clinical trial from which the data came. All the analyses were performed in the 
statistical software Stata 15.1 (StataCorp, College Station, TX). 
 
3.3.6 Human subjects rights protection. This study analyzed clinical and radiological 
data already obtained in previous trials. These clinical studies were reviewed and 
approved by their corresponding IRBs. Additionally, this secondary analysis was also 
approved as a separate study by the main IRB of the Universidad Peruana Cayetano 
Heredia (FWA 0000525). We analyzed all data without personal identifiers to ensure 
patient confidentiality.  
  






2.4  RESULTS 
 
From 220 participants in the parent trials, 73 were excluded: in 47 of them, no 
cysts resolved after antiparasitic treatment, 18 did not have the 12-month CT scan 
performed, 6 did not have MRI at 6 months, and another 2 were determined to have brain 
lesions that were not NCC (study flowchart, Figure 2.7.2). The 147 participants that were 
retained, therefore, all had at least one cyst that resolved six months after antiparasitic 
treatment, and had complete MRI and CT follow up.    
 
Baseline characteristics of study participants are shown in Table 2.7.1. Included 
participants had a mean age of 32 years (SD: 12.2), 95 (64.6%) were male, and the 
median time of pre-existing seizures was 24 months (range: 0.9-294). Eighty patients 
(54.4%) had three or more viable cysts at baseline, and 95 (64.6%) had four or more 
EITB antibody bands. Previous antiparasitic treatment and previous use of antiepileptic 
drugs were reported by 14 (9.5%) and 71 (48.3%) patients respectively. Seventy-six 
patients (51.7%) received standard-dose ABZ, 29 (19.7%) received increased-dose ABZ, 
and 42 (28.6%) received standard-dose ABZ plus PZQ. The median daily dose of 
dexamethasone was 6.5 mg/day (range: 4.5-10). The duration of dexamethasone therapy 
was 10-12 days in 123 participants (83.7%) and 28 days in 24 participants (16.3%), with 
all of the latter receiving >6.5 mg per day. Characteristics of included and non-included 
patients at baseline were not statistically different with the exception that more 
participants that were excluded had a history of prior antiparasitic therapy than those who 
were included (20.6% [15/73] versus 9.5% [14/147], p=0.023. 
 
Of the 147 participants, 92 (62%) had complete cyst cure, 38 (25.8%) had 
incomplete cyst resolution and were not re-treated with antiparasitic treatment before CT 
at month 12, and 17 (11.6%) had incomplete cyst resolution and were re-treated before 
CT exam.  
 





Among the 147 included participants, 497 cysts resolved after antiparasitic 
treatment. From these, 188 calcified lesions were detected by CT in the topographic area 
corresponding to the original viable cyst 12 months after treatment, representing a 
proportion of cyst calcification of 37.8% (95% C.I.: 33.68-42.17). The proportions of 
cysts resulting in calcification according to study covariates are shown in Table 2.7.2.  
 
We evaluated 18 self-selected patients with complete resolution of viable cysts 
who had 6-month MRI and 12-months CT scan evaluation. Subsequently, these patients 
had an additional long-term CT scan evaluation (mean time 3.6 years [1.0y - 6.6y]. These 
participants had 79 viable cysts at time zero that resolved when seen at the 6-month MRI, 
and 21 cysts (26.6% 21/79) that had calcified at the 12-month CT scan. In the long-term 
follow-up CT scan we found 3 (3.4% 3/79) new calcified lesions (in three different 
participants) among the resolved cysts evaluated at month six that did not show 
calcification at month 12. 
 
In univariate analysis, variables at the cyst level significantly associated with risk 
of calcification included: cyst size greater than 14 mm, the location of cyst in the parietal 
lobe, and the presence of surrounding edema. At the patient level, the risk of calcification 
was associated with having seizures for more than 24 months, having 3 or fewer reactive 
antibody bands on EITB, receiving an increased dose of ABZ compared to combined 
treatment (ABZ plus PZQ), receiving a daily low dose of dexamethasone (less than 6.5 
mg/patient), and not having received re-treatment in the presence of incomplete cyst 
resolution at month 6 (Table 2.7.2). 
 
Multivariate analyses, model 1, included cyst covariates only, and demonstrated a 
significantly higher risk of residual calcification for cysts with a diameter greater than 14 
mm (RR: 1.30 [95% CI: 1.07-1.57, p=0.007]) and for cysts with surrounding edema (RR: 
1.36 [95% CI: 1.16-1.59, p<0.001]). In model 2, which also included patient level 
covariates, the risk of calcification remained higher for cysts larger than 14 mm (RR: 
1.34 [95% CI: 1.02-1.75, p=0.035]) and for cysts with surrounding edema (RR: 1.39 
[95% CI: 1.05-1.85, p=0.023]). Additional patient-level covariates associated with a 





greater risk of calcification, model 2, included having a history of more than 24 months 
with seizures (RR: 1.25 [95% CI: 1.08-1.46, p=0.003]), having fewer than four reactive 
antibodies bands on EITB (RR: 1.14 [95% CI: 1.02-1.27, p=0.020]), receiving an 
increased dose of ABZ compared to combined treatment with ABZ plus PZQ (RR: 1.26 
[95% CI: 1.14-1.39, p<0.001]), and receiving lower doses of dexamethasone (RR: 1.36 
[95% CI: 1.02-1.81, p=0.037). Receiving standard-dose ABZ was not associated with a 
different risk of calcification compared to combined treatment.  
 
Interestingly, the proportion of calcification in cysts that resolved after antiparasitic 
treatment was lower in individuals who had incomplete cyst cure and receive re-
treatment, compared to both participants with incomplete cure who did not receive re-
treatment (RR: 1.45 [95% CI: 1.08-1.93, p=0.012]) and to participants with complete 
cure at month 6 (RR: 1.48 [95% CI: 1.29-1.71, p<0.001]) (Table 2.7.2) 
 
  






2.5 DISCUSSION  
 
Despite the important role of post-treatment calcifications in the pathogenesis of 
seizures and resulting morbidity in NCC, there is still very little knowledge about how 
common this outcome is and how it can be avoided. This study shows that approximately 
two of each five (37.8%) viable brain parenchymal cysts result in residual calcification 12 
months after antiparasitic treatment. In addition, the design of our study allowed a 
systematic assessment of factors associated with residual calcification. Large cysts, and 
cysts with perilesional edema prior to treatment, were more likely to result in 
calcification. Other factors associated with increased risk of calcification include a longer 
duration of disease (epilepsy), a mild antibody response, increased doses of ABZ versus 
combined antiparasitic treatment (ABZ-PZQ), lower doses of corticosteroids, and lack of 
antiparasitic re-treatment among those with incomplete cyst cure.  
 
While there are multiple reports of the frequency of residual calcification in 
Indian patients with a single degenerating brain cysticercus, that is a milder presentation 
of NCC.
91, 95, 152, 166, 171, 174-179
 Few studies have reported the proportion of viable 
parenchymal cysts resulting in calcification after antiparasitic treatment compared with 
placebo. In a prior study by our group, the proportions of residual calcifications were 
higher than what we report here, at 62% and 38.4% for the ABZ and placebo groups 
respectively.
25
  In that study, however, the occurrence of calcifications was measured at 2 
years (versus 12 months here), a difference that might explain the higher proportions of 
observed calcification.  Carpio et al. 
26
 found 81.8% and 76.7% after a year of follow up 
in the albendazole versus placebo group, respectively, and showed similar proportion of 
calcification at the one and six month evaluations. On the other hand Das et al.
24
 followed 
patients for 5 years after antiparasitic treatment and showed that the likelihood of 
calcification increased over time from 13.5% to 33.8% at 1 and 5 years, respectively, 
after antiparasitic treatment versus 9.3% to 22.7% at 1 and 5 years of follow up in the 





placebo group. We only found an increment of 3.4% of calcification in a span of 2 to 6 
years after treatment in a subgroup of patients.      
 
Overall, the factors associated with the development of a calcified lesion suggest 
a significant role of the host inflammatory reaction in the pathogenesis of calcification, 
including baseline perilesional edema (reflecting significant ongoing inflammation), the 
use of lower corticosteroid doses (poorer modulation of inflammation), larger cysts 
(greater host exposure to parasite antigen), use of a higher dose of ABZ (causing 
important cyst damage but not lethal effects such as is seen with ABZ-PZQ and thus 
enhancing and extending inflammation), or lack of antihelmintic retreatment (failing to 
eliminate cyst remnants).  
 
Our findings are consistent with those reported for solitary cysticercus granuloma 
(SCG), in which moderate to severe baseline edema is strongly associated with 
subsequent calcification (OR 3.3 95%CI 1.50–7.36).
165
 However, patients with SCG who 
received anti-inflammatory treatment compared to a conservative approach (symptomatic 
treatment), both in the absence of antiparasitic treatment, have similar rates of 
calcification.
176-180
  However, in some of these studies the CT scans were done only 2 to 6 
months after intervention, likely underestimating the rates of calcification and missing 
any differential effect.  
 
An increased-dose ABZ was associated with a higher risk of subsequent 
calcification, compared to combined ABZ plus PZQ, or standard dose ABZ. Since this 
regime was more effective than standard dose ABZ but less effective than combined 
ABZ plus PZQ, we are tempted to hypothesize that increased-dose ABZ causes greater 
damage and exposition of antigens than standard-dose ABZ (thereby requiring a 
prolonged, enhanced inflammatory reaction and thus more calcification), but does not 
reach the high efficacy levels of combined ABZ plus PZQ. In the combined ABZ plus 
PZQ group, the simultaneous use of two antiparasitic drugs may promote more 
aggressive damage to the cyst, and faster parasite death, reducing the overall time with 
inflammation.  






In individuals who did not cure all their cysts (assessed at month 6 after 
treatment), a new course of treatment is indicated. Some, but not all of these individuals 
received early courses of retreatment (6 to 10 months after the first course of treatment). 
Interestingly, early retreatment was strongly associated with lower proportions of 
subsequent calcification for the subgroup of cysts that had already resolved by month 6.  
Resolved cysts that were not exposed to a second course of treatment were 1.5 times 
more likely to result in calcification than those that were exposed to a second treatment. 
This phenomenon would be equivalent to what occurs in NCC patients with a single 
enhancing lesion, in which the cyst has already started the degenerating process. The use 
of ABZ in these individuals results in less residual calcification.
95, 171
 There is no clear 
mechanistic explanation for why the use of antiparasitic treatment in an already dying 
parasite can help to decrease the proportion of calcified lesions. One possible explanation 
is that antiparasitic treatment helps eliminate active or living parasite remnants that 
continue causing an inflammatory reaction.  
 
This study has limitations. While MRI is the best neuroimaging modality to assess 
the viability of cysts, and CT scan allows more prominent visualization of calcifications, 
the sensitivity and specificity of these neuroimaging techniques are not perfect. 
Participants in the original trials may have been evaluated using different neuroimaging 
machines and this could have introduced a measurement bias. However, this was likely a 
non-differential bias that did not significantly alter the results observed in this study. 
Although there was some loss to follow-up in the original trials, this was also likely non-
differential in nature.  
  








This study adds important evidence to understand the factors involved in the 
calcification process, and suggests that inflammation plays a key role. Because residual 
calcification clearly increases the risk of epilepsy, clinical interventions to reduce 
calcification may reduce the risk of subsequent seizures and associated morbidity.  The 
differential risk seen with varying regimens of both antiparasitic drugs and 
corticosteroids strongly suggests that that effective antiparasitic treatment aid by an 
optimized control of the resulting inflammatory reaction may mitigate the calcification 
process, reducing future seizure recurrence. The application of combined ABZ-PZQ 
treatment, higher doses of corticosteroids, and early re-treatment in patients with partial 
or even complete cure may result in lower rates of calcification, and should be tested in 










2.7 ANNEXES  
FIGURES 
Figure 2.7.1. Consecutive T2 MRI slides showing two viable cysts at baseline in T2 MRI (left), 
both lesions resolve by month 6 after antiparasitic treatment (middle), and only the bigger cyst 























Table 2.7.1 Demographic, clinical and radiological characteristics of included and excluded 









 32.0 ± 12.2 33.6 ± 12.8 0.367 
Sex Female 52 (35.4%) 28 (38.4%) 
0.665 
Male 95 (64.6%) 45 (61.6%) 
Disease time (months)
 ‡
 24 (0.9-294) 24 [0.1-181] 0.329 
Basal cysts 1-2 cysts 67 (45.6%) 36 (50.7%) 
0.477 
 ≥3 cysts 80 (54.4%) 35 (49.3%) 
Basal 
calcifications 
None 42 (28.6%) 17 (26.2%) 
0.717 
1 or more 105 (71.4%) 48 (73.8%) 
EITB bands
b
 ≤3 bands 52 (35.4%) 20 (27.4%) 
0.265 
>3 bands 95 (64.6%) 53 (72.6%) 
Previous APT No 133 (90.5%) 58 (79.5%) 
0.023 
 Yes 14 (9.5%) 15 (20.5%) 
Previous AED  No 76 (51.7%) 33 (45.2%) 
0.364 
 Yes 71 (48.3%) 40 (54.8%) 
APT scheme ABZ+PZQ 42 (28.6%) 15 (20.6%) 
0.202  Standard ABZ 76 (51.7%) 47 (64.4%) 
 Increased ABZ 29 (19.3%) 11 (15.1%) 
Days with APT 10 days 102 (69.4%) 54 (74.0%) 
0.481 
 14 days 45 (30.6%) 19 (26.0%) 
Dose DEXA (mg/d)
 ‡
 6.5 (4.5-10%) 6.5 (4-10%) 0.403 
Days with DEXA 10-12days 123 (83.7%) 65 (89.0%) 
0.288 
 28 days 24 (16.3%) 8 (11.0%) 
 
Abbreviations: APT (antiparasitic treatment), AED (antiepileptic drug), ABZ(albendazole), PZQ 















Table 2.7.2  Risk ratios (RR) for the development of residual calcifications after antiparasitic treatment in 






Univariate models Multivariate model 1
b
 Multivariate model 2
b
 
RR (95% CI) p value
c
 RR (95% CI) p value
c
 RR (95% CI) p value
c
 
CYST LEVEL        
Cyst size        
≤14 mm 166/453 (36.6) Ref.  Ref.  Ref.  
>14 mm 22/44 (50.0) 1.35 (1.14-1.60) <0.001 1.30 (1.07-1.57) 0.007 1.34 (1.02-1.75) 0.035 
Cyst content        
Clear 158/435 (36.3) Ref.      
Turbid 30/62 (48.4) 1.30 (0.18-2.15) 0.313     
Cyst location        
Frontal lobe 67/172 (39.0) 1.02 (0.78-1.35) 0.866     
Parietal lobe 60/182 (33.0) 0.82 (0.67-1.00) 0.047     
Occipital lobe 27/63 (42.9) 1.13 (0.85-1.52) 0.402     
Temporal lobe 36/98 (36.7) 0.98 (0.70-1.38) 0.902     
Cyst edema        
No 125/365 (34.3) Ref.  Ref.  Ref.  
Yes 63/132 (47.7) 1.37 (1.17-1.62) <0.001 1.36 (1.16-1.59) <0.001 1.39 (1.05-1.85) 0.023 
PATIENT LEVEL      
  
Age (tertiles)        
16 to 25 years 67/177 (37.9) Ref.      
26 to 35 years 56/156 (35.9) 0.98 (0.69-1.38) 0.899     
>35 years 65/164 (39.6) 1.03 (0.81-1.32) 0.796     
Sex        
Female 63/172 (36.6) Ref.      
Male 125/325 (38.5) 1.04 (0.83-1.30) 0.733     
Disease time        
≤24 months 79/229 (34.5) Ref.    Ref.  
>24 months 109/268 (40.7) 1.17 (1.13-1.21) <0.001   1.25 (1.08-1.46) 0.003 
N
o
 of Cysts        
1 to 2  38/78 (48.7) Ref. Ref.     
3 or more  150/419 (35.8) 0.74 (0.44-1.25) 0.261     
No of Calcifications 
at baseline 
     
  
None 39/98 (39.8) Ref.      
1 or more 149/399 (37.3) 0.95 (0.55-1.69) 0.891     
EITB bands        
≥4 bands 140/388 (36.1) Ref. Ref.   Ref.  
≤3 bands 48/109 (44.0) 1.21 (1.14-1.28) <0.001   1.14 (1.02-1.27) 0.020 
Previous APT        
No 173/440 (39.3) Ref.      
Yes 15/57 (26.3) 0.69 (0.36-1.30) 0.249     
Previous AED         
No 92/254 (36.2) Ref.      
Yes 96/243 (39.5) 1.11 (0.99-1.23) 0.064     
APT scheme        
ABZ+PZQ 78/224 (34.8) Ref.    Ref.  
Standard ABZ 73/190 (38.4) 1.09 (0.84-1.41) 0.525   1.04 (0.71-1.51) 0.861 










Univariate models Multivariate model 1
b
 Multivariate model 2
b
 
RR (95% CI) p value
c
 RR (95% CI) p value
c
 RR (95% CI) p value
c
 
Days with APT        
10 days 136/361 (37.7) Ref. Ref.     
14 days 52/136 (38.2) 0.99 (0.88-1.13) 0.958     
Dose of DXM        
>6.5  mg /day 71/217 (32.7) Ref. Ref.   Ref. Ref. 
≤6.5 mg /day 117/280 (41.8) 1.26 (1.04-1.52) 0.018   1.36 (1.02-1.81) 0.037 
Days with DXM        
10-12 days 163/429 (38.0) Ref. Ref.     
28 days 25/68 (36.8) 0.95 (0.86-1.06) 0.366     
Cyst cure  
and re-treatment 
       
Incomplete cure and 
re-treated 
19/66 (28.8) Ref. Ref.   Ref. Ref. 
Complete cure and 
not re-treated 
111/280 (39.6) 1.41 (1.21-1.63) <0.001   1.48 (1.29-1.71) <0.001 
Incomplete cure and 
not re-treated 




Risk ratio (RR), Confidence interval (CI), Electro immunotransfer blot  (EITB), Antiparasitic treatment (APT), 
Antiepileptic drugs (AED), Albendazole (ABZ), Praziquantel (PZQ), Dexamethasone (DXM). 
 
†
Risk ratios from univariate and multivariate models were estimated using multilevel Poisson regression with 
random-effects for individual intercepts. 
 
‡
Multivariate multilevel Poisson regression model 1 initially included all covariates at the cyst level using a 
stepwise approach with backward selection algorithm to retain covariates with p value <0.05 for Wald Test.  
 
#
Multivariate multilevel Poisson regression model 2 included covariates retained in model 1 and all 
covariates at the patient level using a similar stepwise approach for selection of covariates. 
 
All regression models were estimated using mean-variance adaptive Gauss-Hermite quadrature with seven 
integration points for each level of random effects. Standard errors were estimated with cluster-robust 
variance estimates to allow extra correlation due to the original trial from which the data came.    
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3.1 ABSTRACT  
 
3.1.1 Introduction: Neurocysticercosis (NCC), an infection of the central nervous 
system with the larval vesicles of the parasite Taenia solium, is a leading cause of 
acquired epilepsy worldwide. Viable cysts in the brain parenchyma often follow a 
degenerative progression and eventually resolve completely or leave a calcified scar. 
Some patients with calcified NCC lesions develop epilepsy, and a proportion of them 
present breakthrough seizures despite appropriate treatment with antiepileptic drugs 
(AED). This study assessed the incidence and risk factors of breakthrough seizures (BTS) 
in patients with epilepsy due to NCC.  
 
3.1.2 Methods:  In this prospective cohort study, we assessed the incidence of and risk 
factors for BTS in adults with epilepsy and calcified NCC. We assembled a cohort of 
patients with neurological symptoms and calcified NCC as determined by computed 
tomography (CT) scan. Participants in this cohort received clinical examination, 
electroencephalogram (EEG), and enzyme-linked electroimmunotransfer blot (EITB) for 
detection of anticysticercal antibodies in serum. They were contacted by telephone every 
two weeks and had clinical evaluations every three months. From this main cohort, we 
selected the sub-group of individuals with epilepsy who were receiving AED, as 
indicated by their attending neurologist. These participants were followed until a BTS 
(event), withdrawal of AED, loss to follow-up, or administrative censoring. All seizures 
were classified according to the ILAE guidelines. 
 
3.1.3 Results: The study cohort was composed by 210 patients that fulfilled the inclusion 
criteria, of which 103 (49.1%) presented BTS during the follow-up. The predefined 
maximum follow-up time was 36 months with a median of 10.8 months (total of 
observed months at risk were 2,915). The mean age was 36.3 ± 13.1 years old and 102 
(48.6%) were male. In time-to-event analysis the Kaplan-Meier plot showed that only 
36% (95% CI: 27.2%-44.9%) remained free of seizure during the study time and most of 
the events (91.2%, 94/103) occurred within the first 2 years of follow-up. In the initial 





univariate Cox analysis we found that eight participants had an abnormal interictal EGG 
and they had a HR of BTS 9.2 times higher than the rest, and since they represented s 
different group we decide to exclude these eight participants for further characterization 
of other risk factors. In the remaining 202 participants univariate Cox analysis showed 
that risk factors for BTS included: being female (HR: 1.50 p=0.049), having a history of 
calcification without antiparasitic treatment prior to enrollment (HR 1.44 p=0.067), 
history of at least one seizure event in the past year prior to enrollment (HR: 2.91 
p<0.001), and history of 10 or more seizures (HR: 1.77, p=0.006). The multivariate 
analysis showed similar trends, but only having a seizure event in the past year (HR: 2.69 
p<0.001) and a history of 10 or more seizure events (HR 1.55 p= 0.038) remained 
statistically significant.  Being female and having calcified lesions in the temporal lobe 
were associated with an increased risk for BTS relapse, but with marginal significance 
only.  
 
3.1.4 Conclusions: Control of seizures with AED drugs in patients with calcified NCC is 
suboptimal. Survival time analysis showed that only 36% remain free of seizure after a 
follow-up of three years. Main risk factors for BTS were having a seizure within one year 
before enrollment, history of 10 or more seizures, and having an abnormal inter-ictal 
EEG. Our findings should orientate an individualized clinical management of patients 
with calcified NCC in a higher risk of BTS, which represent enduring epileptogenic foci.    





3.2 INTRODUCTION  
 
When cysticerci, the larvae of the pork tapeworm Taenia solium, infect the central 
nervous system, the disease is known as neurocysticercosis (NCC). NCC is the single 
most important factor associated with acquired epilepsy in developing countries, and 
probably in the world, and is thus an important public health problem.
164
  Cases of 
symptomatic NCC are frequently seen in hospitals in endemic countries, and a consistent 




Larvae establish infection in the brain parenchyma by forming cystic structures, 
known as viable cysts when the parasite is alive. Over time, the cysts may degenerate, 
either resolving completely or leaving small, calcified scars in the brain. Brain 
calcifications are known to cause seizures, although the mechanisms are not well 
understood. Because calcifications can remain in the brain long after the parasite has 
died, perhaps even for the entire lifespan of the host, they accumulate in the population in 
endemic regions and are thus a major contributor of seizure burden. 
 
Breakthrough seizures (BTS) are described as new seizure events that occur 
suddenly and unexpectedly after a seizure-free period, despite regular use of AED.
139, 181
 
BTS occur in about 30% of persons with epilepsy (PWE) from causes other than NCC.
182
  
Risk factors associated with BTS include experiencing multiple seizures before achieving 
control, presence of a concomitant neurological disorder, family history of epilepsy, and 
presence of a paroxystic EEG. Other potential causes include poor adherence to AED, 
concomitant inflammatory conditions or infections, emotional stress, use of medications 
that lower the seizure threshold, sleep deprivation, menstruation, diarrhea, metabolic 
events, flashing lights, etc.
139-141
 Although BTS are common among PWE due to calcified 
NCC, these events and their risk factors have not been systematically studied among this 
group.
28, 96, 142
   The incidence of BTS in calcified NCC has been reported to be 24% to 










In this study, we evaluated the incidence, cumulative incidence, and predictive 
factors of BTS in a cohort of patients with cerebral NCC calcifications and a well-
established diagnosis of recurrent non-provoked seizures (epilepsy). Our results may help 
to identify the subpopulation of individuals with calcified NCC at increased risk of BTS, 
in order to implement individualized therapeutic approaches.   
  
  






3.3 MATERIAL AND METHODS 
 
3.3.1 Study design and objective.   The objective of this prospective cohort study is to 
assess the incidence rate and cumulative incidence of BTS, as well as associated factors, 
in patients with epilepsy and calcified NCC.  
 
3.3.2 Study population and selection criteria. This hospital-based study comprised 
adult patients who are part of a larger parent cohort of participants with calcified 
parenchymal NCC. This parent cohort started in 2012 and consecutively enrolled patients 
with calcified NCC and neurological symptoms (Figure 3.7. 1). From the parent cohort 
we selected a sub-group to evaluate incidence of and risk factors for breakthrough 
seizures BTS. Both men and women greater than 16 years of age were eligible for the 
BTS cohort. Other inclusion criteria were having been diagnosed with calcified 
parenchymal NCC using a non-enhanced brain CT, having acquired epilepsy as defined 
by ILAE (with a history two or more seizures),
105
 and being currently under AED 
therapy. Exclusion criteria were having recurrent non-provoked seizures (not related to 
NCC), presence of viable and/or degenerating NCC lesions in the brain parenchyma, 
subarachnoid spaces, or ventricles, having a positive antigen ELISA result suggesting the 
presence of viable parasites,
183
 intracranial hypertension or hydrocephalus, focal 
neurological deficits, dual neurological pathology (NCC + Stroke, or NCC + cortical 
dysplasia, etc.) and pregnancy. Participants with viable and/or degenerating cysts 
received their diagnostic test results and images and were referred for appropriate 
medical treatment. 
 
3.3.3 Study activities. Participants received medical consultation by a team of study 
physicians, who collected clinical information regarding seizure history (months since 
first seizure, seizure-free months before enrollment, number of previous seizures, 
description of seizures, and family history of seizures) and prior use of cysticidal drugs. 
Brain CT scans were read first by the study physician, and subsequently by a 





neuroradiologist who confirmed the number, location, and size of calcified lesions, and 
ruled out the presence of viable and/or degenerating cysts. Any discrepancies between 
reviewers were resolved by consensus. Patients also had an EEG, serum enzyme-linked 
electroimmunotransfer blot (EITB) assay for antibody detection,
55
 and serum ELISA for 
antigen detection.
183
   
 
The follow-up period was 36 months per patient, with censoring occurring for any 
of the following endpoints: AED withdrawal, loss to follow-up, or administrative 
censoring (36 months of follow-up or study end date of November 30, 2017), and the 
event was the occurrence of a BTS. Participants in the parent cohort were evaluated at the 
study site every three months, and the study team also followed them by phone contact 
every two weeks. All patients and close relatives were instructed to recognize and 
immediately report to the study team any event suggesting a seizure, and were given a 
diary that was reviewed by the study team at each clinical visit. A diagnosis of seizure 
was made initially by a study physician who interviewed the patient during the visit, with 
subsequent verification of the diagnosis by a study neurologist. Seizure events were 
classified according to the 2010 ILAE classification.
105
 Further classification of epilepsy 
according new ILAE in 2017
106
 did not change the seizure classification used in this 
study.       
 
3.3.4 Outcome assessment. The primary outcome was the presence and timing of BTS. 
Cumulative incidence, incidence rate, and the survival curve were estimated in a time-to-
event analysis during the time period between enrollment until event or censoring.  
 
3.3.5 Covariates. We included the following covariates in our analysis: age in years 
(continuous variable and also as categories using tertiles), gender, prior antiparasitic 
treatment for viable NCC (yes/no), months since first seizure (continuous variable and 
also as dichotomous using >36 months), seizure-free months before enrollment 
(continuous variable and also as dichotomous variable using >12 months), number of 
prior seizures (discrete variable and also dichotomous variable using >10 seizures), 
family (first-degree relatives) with history of seizures (yes/no), personal history of 





seizures (focal seizures/generalized seizures or focal seizures with generalization), EEG 
results (normal/abnormal), EITB result (≤3 reactive bands/≥4 reactive bands), number of 
calcifications (discrete variable and also as categories 1/ 2-10 / >10), size of calcifications 
(dichotomous; at least one large calcification [having a diameter >10 mm in at least one 
axis axial, coronal and/or sagittal planes]), and presence of edema around the 
calcification (dichotomous; at least one calcification had basal perilesional edema) and 
location of calcifications: frontal/other, parietal/other, occipital/other, and temporal/other.  
(See table 3.7.1)  
 
3.3.6 Statistical analyses. Data was entered in Stata/IC 15.0 (Stata Corp, College Station, 
TX, US) for statistical analyses. Patient characteristics were described using summary 
statistics (categorical variables were expressed as percentages, whereas continuous and 
discrete variables were expressed using mean ± standard deviation or median and ranges 
respectively). The overall incidence of BTS in the cohort was reported with 95% 
confidence intervals, and compared between patient covariates using two-sample 
parametric or non-parametric tests as appropriate. The following definitions were applied 
for survival analysis: time origin – date of enrollment; time metric – duration of follow-
up in months; and event – seizure reported by the patient and confirmed by the study 
neurologist. Cumulative event-free survival curves with 95% confidence intervals were 
calculated using the Kaplan – Meier method, and the log-rank test was used to compare 
survival curves by covariate. We also fitted Cox proportional hazard regression models to 
estimate hazard ratios (HR) of having BTS. First, bivariate models were performed, and 
then, a multivariate model was performed using a backward-stepwise approach for 
selection of covariates considering a p-value<0.05 from the Wald test. The proportional 
hazard assumption from the final model was assessed using the Schoenfeld residuals test 
and complementary log-log plots (Figure3.8.2). Predicted survival functions after Cox 
regression were also plotted.  
 
3.3.7 Human subject rights protection. The parent cohort study was reviewed and 
approved by the IRBs of the Universidad Peruana Cayetano Heredia and of National 
Institute of Neurological Sciences, both in Lima, Peru. The participants were enrolled 





after an informed consent process which included signing a written consent form. All 
study personnel who had contact with subjects or data completed a course on human 










3.4 RESULTS  
The BTS cohort included individuals followed from January 2012 to November 
2017. As shown in the study flowchart (Figure 3.7.1), the original parent cohort was 
composed of 368 patients with NCC and neurological symptoms. The inclusion criteria 
for the BTS cohort included patients with calcified NCC, diagnosis of epilepsy and AED 
treatment; 177 individuals met the inclusion criteria and were selected in 2012. 
Subsequently, 33 of the 191 remaining individuals in the parent cohort became eligible 
during the follow-up period and were admitted into the BTS cohort. Of the 33, 26 began 
AED treatment for their existing diagnosis of epilepsy during the follow-up period, and 7 
with a history of a single or no seizure subsequently developed a second seizure (5) or 
two or more seizures (2), thereby fulfilling the criteria of recurrent non-provoked seizures 
and starting their AED treatment. The final number of participants in the BTS cohort was 
210 (Figure 3.7. 1). 
 
Demographic, clinical, and neuroimaging characteristics of the BTS cohort are 
shown in Table 3.7.1. Participants had a mean age of 36.3 ± 13.1 years and 102 (48.6%) 
were men. The median time-period of having seizures was 79 months before enrollment 
(Interquartile range IQR: 36-181), and the median seizure-free time-period before 
enrollment was 6 months (IQR: 1-22). Participants had a median of 10 seizures prior to 
enrollment (IQR range: 3-33), and the majority of cases (81.9% [172/210]) reported 
having experienced at least one generalized seizure, or a focal seizure with secondary 
generalization. Twenty-six participants (12.4%) had a family history of seizures, and only 
eight (3.9%) had an abnormal EEG (focal abnormalities 5/8 and diffuse abnormalities 
3/8). Fifty (23.8%) had a serum EITB result of ≥4 bands. Participants had a median of 3 
(IQR: 1-10) calcifications detected by brain CT scan, and 38 (18.2%) had at least one 
lesion with perilesional edema. Calcifications were more often located in frontal lobes 
(164/210; 78.1%). Thirteen patients (6.2%) had at least one large lesion.  
 





Of the 210 participants in the cohort, 103 presented new seizures during the 
follow-up period, with almost all events (94/103) occurring during the first 2 years of 
follow-up. The cumulative incidence of BTS was 49.1% (95% CI: 42.3%-55.8%). In the 
bivariate analysis using chi square test, individuals with BTS were likely to be female 
(p=0.027), to have had a shorter time-period (≤ 12 months) without seizures before 
enrollment (p<0.001), to have a history of more than 10 events (p=0.007), to have 
reported at least one episode of generalized seizures or focal seizures with generalization 
(p=0.017), and to present edema around at least one calcified lesion (p=0.024). Other 
characteristics were not significantly different between patients with and without BTS 
during the follow-up period (Table 3.7.1).  
 
Survival analysis showed a total time at risk in the cohort of 2,915 months, with a 
median follow-up time per subject of 10.8 months (IQR: 3.9-20.5 months).  107 patients 
were censored in this study: only 9 out of 210 (4.3%) were lost to follow-up, 51 
underwent administrative censoring (22 due to date to study end and 29 fulfill 3 years of 
follow-up), and 47 stop their AED. The median seizure-free time in the cohort was 20.2 
months (95% CI: 13.5-30.7). The Kaplan-Meier survival estimator showed that only 
36.0% (95% CI: 27.2%-44.9%) remained free of seizures during the follow-up period 
(Figure 3.7.2).  Given that 6 out of 8 participants with abnormal interictal EEG at 
baseline presented with BTS during the follow-up and five of these seizure events were 
observed within the first 6 months (Figure 3.7.3), we decide to exclude these eight 
participants for further characterization of risk factors for BTS.   
 
Survival curves in the remaining 202 participants were statistically different 
between men and women, between patients with >12 and ≤12 months free of seizures 
before enrollment, and between those with >10 and ≤10 previous seizure episodes 
(Figure 3.7.4).  
 
Analysis of risk factors for BTS is shown in Table 3.7.2. In univariate Cox 
regression models, significant risk factors for BTS included being female (HR: 1.50 [95% 
CI: 1.00-2.25], p=0.049), having 12 or less months free of seizures before enrollment 





(HR: 2.91 [95% CI: 1.82-4.66], p<0.001), and having had more than 10 prior seizure 
episodes (HR: 1.77 [95% C I: 1.18-2.66], p=0.006). We also observed a trend of having 
calcification as result of natural evolution (without antiparasitic treatment) of the cyst but 
without statistical significance (HR: 1.31 [95% CI: 0.86-1.97], p=0.194).  
 
After performing a multivariate model using a stepwise approach with backward 
selection, starting with a model that included all covariates and retaining variables with a 
p<0.05 from the Wald test, only two variables remain as significant risk factors for BTS; 
having a seizure-free time period ≤12 months (HR: 2.69 [95% CI: 1.67-4.34], p<0.001) 
and having had >10 previous seizures (HR: 1.55 [95% CI: 1.02-2.33], p=0.038), see 
Table 3.7.2. Schoenfeld’s residuals tests and the plots of observed-versus-predicted 
survival curves corroborated the proportional-hazards assumption for covariates included 
in the multivariate analysis (Supplementary Information 3.8).  
  






3.5 DISCUSSION  
 
This prospective cohort study demonstrates a high frequency of BTS in PWE due 
to calcified NCC, with a total proportion around 50%. Survival analysis showed that only 
36% remain free of seizures during 3-year follow-up period. Significant risk factors for 
BTS in the multivariate Cox regression model included having more prior and more 
recent seizures events (having a history of ten or more seizures, and having at least a 
seizure event within the previous year). An abnormal interictal EEG was strongly 
associated with BTS and most of these participants (6/8) presented BTS in the first year 
of follow up. Due to this particular characteristic, these participants with abnormal EEGs, 
were excluded from further univariate and multivariate time-to event analysis.  
 
In PWE and with calcified NCC, the existing literature reports rates of BTS that 
are difficult to directly compare with our study results mainly because of differences in 
participant characteristics (number of calcifications) and follow-up time. Sharma et al.
8
 
reported a cohort of 35 patients with newly diagnosed epilepsy and single calcification, 
finding a cumulative incidence of BTS 34.3% in a follow-up time of 6 months. Singh et 
al.
142
 studied a cohort of 54 PWE and single calcified lesions receiving AEDs who were 
followed-up for one year, and showing a BTS cumulative incidence of 24.04% (13/54). 
Nash and collaborators reported a 5-year longitudinal study with 110 patients with 
multiple calcified lesions. They reported seizure incidence of 36%; however, this study 
included a mix of patients with (60) and without (50) AED treatment. Patients taking 




The cumulative hazard of BTS observed in our study is greater than that reported 
in the literature for epilepsy caused by causes other than NCC, in which 60% - 70% of 
patients respond to AEDs, effectively controlling their seizures.
184, 185
  In those non-NCC 
patients, poor seizure control has been associated with factors such as early onset of 





epilepsy, epilepsy of unknown cause, seizure semiology, higher numbers of seizures, 




A strong predictor of BTS was to have an abnormal interictal EEG. Six of eight 
participants with abnormal EEG experienced BTS, with most occurring within the first 6 
months of follow-up (5/6). Sub-analyses showed that abnormal EEG was strongly related 
with longer duration of disease; 7/8 had more than 36 months of disease (epilepsy) and 
all (8/8) had three or fewer bands on EITB. Sharma et al.
8
 also report an abnormal EEG 
as a risk factor for BTS in NCC, and in non-NCC-related epilepsy, abnormal EEG has 




The main predictor of BTS in our study was to have a seizure episode in the year 
prior to enrollment. These participants were three times more likely to have a 
breakthrough seizure than those who were seizure-free for more than 12 months. Having 
a history of frequent (ten or more) episodes of seizures before enrollment was also a 
strong predictor of BTS. It has been consistently described by the literature, in both NCC-
related and non-NCC-related epilepsy, that several episodes of seizures is a potential risk 
factor for BTS.
96, 140-142
   
 
Being female was associated with a higher risk of BTS in univariate analyses, 
while in the adjusted model lose their statistical significance when adjusted by number of 
previous seizure. The tendency for women to have more seizures has been previously 
reported in non-NCC patients. It has been consistently reported that progesterone has an 
antiepileptic effect, while estrogen increases the risk of seizures.
189, 190
  Thus, 
menstruation has been reported as an attributable cause of seizures due to the association 
with progesterone levels. Also, a similar effect occurs during the ovulatory and peri-
ovulatory phases due to an estrogen peak and progesterone withdrawal. Additionally, 
anovulatory periods involve a higher risk of seizure due to high ratio estrogen/ 
progesterone.
189-193
 Sex has not been reported in the literature of calcified NCC and 
BTS.
28, 96, 142
    
 





Consistent with other reports in the literature, our study did not find a relationship 
between the number of calcifications and an increased risk of BTS.
28, 194
 This suggests 
that in patients with several cysts only one or a few lesions are epileptogenic or dominant. 
It argues against the hypothesis that direct calcium toxicity can be the causal effect of 
seizures in calcified NCC, because if seizures events were related to calcium toxicity, the 
epileptic activity should be proportionally related to the number of calcifications. 
However, we did not find this association present in our study, nor has it been reported in 
other studies.
28, 194
 This finding can explain why in endemic areas we found a sizable 




Patients with calcified NCC are frequently seronegative on EITB, since antibodies 
decay and disappear months or years after cyst death.
195, 196
 In community-based studies 
conducted in endemic areas, it is common to find seronegative symptomatic and 
asymptomatic participants with calcified lesions compatible with NCC.
14, 18, 197
  In our 
cohort, there was supporting evidence of NCC in 174/210 participants (159 were positive 
to EITB and 15 had history of antiparasitic treatment for NCC). The remaining 36 
individuals had calcified images compatible with NCC calcifications confirmed by the 
study neuroradiologist, as cerebral calcified lesions due to NCC have a particular 
punctuated and rounded shape. The morphological characteristics of calcified lesions 
among those 36/210 patients without supporting evidence of NCC were similar to those 
of the 174/210 confirmed by serology and/or an antecedent of viable brain cysts. Also, as 
expected, these patients had a longer history of disease and fewer brain calcifications. 
Additionally, a sensitivity analysis excluding those 36 participants did not change the 
main results.  
 
Contrary to the existing literature in PWE not related to NCC,
198
 a family history 
of epilepsy did not represent a risk factor for BTS in this cohort of people with epilepsy 
and calcified NCC under AED treatment. Family history of seizure has a greater role in 
persons with epilepsy with a genetic basis.
199
 While a genetic component for epilepsy 
caused by NCC has been suggested,
200-202
 family history of epilepsy has not been 
consistently demonstrated as a risk factor for BTS in NCC.
28, 96, 142
  






Prior use of cysticidal drugs had only a marginal protective effect. This protective 
role is consistent with literature showing the use of these drugs in viable NCC has a 
beneficial effect in seizure control in the long term.
25, 26, 203
 However, most of this 
information came from non-randomized studies using historical controls, and the 
accuracy of results might be questionable.
71, 72, 204, 205
 In contrast, the results of our BTS 
cohort study provides more robust support for this protective effect. 
   
This study has limitations. The main limitation is a potential for recall bias among 
subjects with epilepsy and calcified NCC, as living with this chronic disease may have 
affected the numbers and type seizures reported at baseline. Another potential bias is that 
the only source of information for patients with generalized seizures is a close relative 
and/or witness that can only partially observe and describe the seizure episode. Thus, 
information bias could also be underestimating the number of events recorded in the 
cohort. This bias may occur in almost all population studies attempting to assess this 
covariable as a risk for BTS. The study physicians were not masked to the radiological or 
clinical information, thus they could had become more prone to identify seizure relapse in 
patients with many calcifications or with large calcifications, or with a history of history 
of severe or recurrent seizures. Thus this cohort may have overestimated the numbers of 
BTS. Additionally, we included patients attending a national referral center for 
neurological diseases in Peru. These represent a subgroup of subjects with NCC who may 
be more likely to have suboptimal seizure control, and because of this, selection bias may 
have been introduced affecting the representativeness of the results. 47 participants had 
censoring because they did stop their AED; however these patients were followed and the 
seizure events were also identified, thus, this group was composed by patients with 
informative censoring.  
  






3.6 CONCLUSION  
 
This prospective cohort provides important evidence that patients with calcified 
NCC and epilepsy provides key evidence for clinical management based on these other 
risk factors.  Participants with abnormal interictal EEG should be considered in high risk 
of presenting with BTS in the short term. In addition, patients with calcification and 
epilepsy presenting with a history of more than ten seizures or with at least one seizure in 
the last year are at higher risk of BTS and should have close follow-up.  Additionally, 
these findings may be extrapolated to other causes of epilepsy caused by brain 














Figure 3.7.1 Flowchart to detail how the study cohort was assembled from the original cohort of 









Figure 3.7.2. Kaplan-Meier survival curve of the study cohort. Dash marks represent censored 






























Figure 3.7.4  Kaplan-Meier survival curves of the study cohort after removing 8 participants with 
abnormal EEG (n=202). 
A. Sex        
 
B. Seizure-free time  
 
 
C. Number of previous seizures 
 
 






Table 3.7.1 Characteristics of the study cohort and comparisons between patients with and 
without breakthrough seizure during follow-up (N=210) 




p     





    Mean ± SD  
    ≤28 years 
    29-40 years 
    >40 years 
 
36.3 ± 13.1 
71 (33.8 %) 
73 (34.8 %) 
66 (31.4 %) 
 
35.3 ± 12.2 
36 (35.0 %) 
40 (38.8 %) 
27 (26.2 %) 
 
37.3 ± 13.9 
35 (32.7 %) 
33 (30.8 %) 






Sex (male) 102 (48.6 %) 42 (40.8 %) 60 (56.1 %) 0.027 
Previous APT (yes) 134 (63.8 %) 60 (58.3 %) 74 (69.2 %) 0.100 
Seizure time before enrollment 
(months)                Median (IQR)  
    >36 months 
 
79 (36-181) 
156 (74.3 %) 
 
79 (31--178) 
72 (69.9 %) 
 
78 (41-200) 




Seizure-free time before 
enrollment (months) 
    Median (IQR) 

















Number of previous seizuresa 
    Median (IQR) 













Family history of seizures 26 (12.4) 11(10.7) 15(14.0) 0.463 
Generalized and/or focal 
seizures with generalization 
172 (81.9 %) 91 (88.4 %) 81 (75.7 %) 0.017 
EITB result ≥4 bands 159 (75.7 %) 73 (70.9 %) 86 (80.4 %) 0.109 
EEG result (Abnormal)b 8 (3.9 %) 6 (5.9 %) 2 (2.0 %) 0.140 
Number of calcifications 
    Median (range) 
    Single calcification 
    2 to 10 calcifications 
    >10 calcifications 
 
3 (1-118) 
70 (33.3 %) 
89 (42.4 %) 
51 (24.3 %) 
 
3 (1-118) 
35 (34.0 %) 
43 (41.8 %) 
25 (24.2 %) 
 
3 (1-74) 
35 (32.7 %) 
46 (43.0 %) 






Perilesional Edema c  38(18.2 %) 25 (24.2 %) 13 (12.2 %) 0.024 
Large calcifications c 13 (6.2%) 7 (6.9%) 6 (5.5) 0.694 
Location of calcifications 
    Frontal lobe 
    Parietal lobe 
    Occipital lobe 
    Temporal lobe 
 
164 (78.1 %) 
115 (54.8 %) 
83 (39.5 %) 
85 (40.5 %) 
 
83 (80.6 %) 
54 (52.4 %) 
44 (42.7 %) 
43 (41.8 %) 
 
85 (75.7 %) 
61 (51.7 %) 
39 (36.5 %) 







Standard deviation (SD), interquartile range (IQR), antiparasitic treatment (APT), enzyme-linked 
immunoelectrotransfer blot  (EITB), electroencephalogram (EEG).  
Bold values are considered statistically significant (p<0.05).  
a 
One observation was missed.   
b 
Six observations were missed.   
c 
At least one calcified lesion  





Table 3.7.2  Risk factors for seizure breakthrough in  patients with calcified NCC and 
epilepsy under antiepileptic drug * 
 
Variables 




HR (95% CI) 
p 
value 
























Seizure time                        >36 months 






Seizure-free time before 































Generalized and/or focal seizures 




















Number of calcifications             Single 









Perilesional Edema c                         No 






Large calcifications c                        No 































*Patients with an abnormal EEG result were excluded for the analyses 
Confidence interval (CI), antiparasitic treatment (APT), enzyme-linked immunoelectrotransfer blot 
(EITB), and electro encephalogram (EEG) 
Bold p values are statistically significant 
c 
At least one calcified lesion 
  





3.8 SUPPLEMENTARY INFORMATION 
 
3.8.1. Table. Kaplan-Meier Survival Probability Estimates  
 
           Beg.          Net            Survivor      Std. 
  Time    Total   Fail   Lost           Function     Error     [95% Conf. Int.] 
------------------------------------------------------------------------------- 
   .26      202      1      0             0.9950    0.0049     0.9654    0.9993 
   .36      201      1      0             0.9901    0.0070     0.9610    0.9975 
   .39      200      3      0             0.9752    0.0109     0.9416    0.9896 
   .43      197      1      0             0.9703    0.0119     0.9351    0.9865 
   .66      196      1      0             0.9653    0.0129     0.9287    0.9833 
   .79      195      1      1             0.9604    0.0137     0.9224    0.9800 
   .85      193      1      0             0.9554    0.0145     0.9161    0.9766 
   .89      192      1      1             0.9504    0.0153     0.9099    0.9730 
   .95      190      1      0             0.9454    0.0160     0.9036    0.9694 
   .99      189      1      2             0.9404    0.0167     0.8975    0.9657 
  1.02      186      0      1             0.9404    0.0167     0.8975    0.9657 
  1.05      185      1      0             0.9354    0.0173     0.8913    0.9619 
  1.12      184      1      0             0.9303    0.0180     0.8851    0.9581 
  1.15      183      1      0             0.9252    0.0186     0.8790    0.9542 
  1.32      182      2      0             0.9150    0.0197     0.8668    0.9463 
  1.41      180      0      1             0.9150    0.0197     0.8668    0.9463 
  1.45      179      1      0             0.9099    0.0203     0.8608    0.9423 
  1.61      178      1      0             0.9048    0.0208     0.8548    0.9382 
  1.78      177      1      0             0.8997    0.0213     0.8488    0.9341 
  1.87      176      2      0             0.8895    0.0222     0.8370    0.9258 
  1.91      174      1      0             0.8844    0.0227     0.8311    0.9216 
  1.94      173      0      1             0.8844    0.0227     0.8311    0.9216 
  2.27      172      1      0             0.8792    0.0231     0.8252    0.9174 
  2.47      171      1      0             0.8741    0.0236     0.8193    0.9131 
  2.53      170      1      0             0.8689    0.0240     0.8135    0.9088 
  2.66      169      1      0             0.8638    0.0244     0.8076    0.9045 
  2.79      168      1      1             0.8586    0.0248     0.8018    0.9002 
  2.86      166      1      0             0.8535    0.0252     0.7960    0.8958 
  2.89      165      2      0             0.8431    0.0259     0.7844    0.8870 
  2.93      163      0      2             0.8431    0.0259     0.7844    0.8870 
  2.96      161      0      1             0.8431    0.0259     0.7844    0.8870 
  3.22      160      0      1             0.8431    0.0259     0.7844    0.8870 
  3.32      159      0      1             0.8431    0.0259     0.7844    0.8870 
  3.39      158      3      0             0.8271    0.0270     0.7665    0.8733 
  3.65      155      0      1             0.8271    0.0270     0.7665    0.8733 
  3.95      154      1      0             0.8217    0.0274     0.7605    0.8687 
  4.04      153      0      1             0.8217    0.0274     0.7605    0.8687 
  4.18      152      1      0             0.8163    0.0277     0.7545    0.8640 
  4.31      151      1      0             0.8109    0.0280     0.7486    0.8593 
  4.41      150      1      0             0.8055    0.0284     0.7426    0.8546 
  4.47      149      1      0             0.8001    0.0287     0.7367    0.8498 
   4.5      148      0      1             0.8001    0.0287     0.7367    0.8498 
  4.77      147      1      0             0.7947    0.0290     0.7307    0.8451 
     5      146      1      0             0.7892    0.0293     0.7247    0.8403 
   5.1      145      0      2             0.7892    0.0293     0.7247    0.8403 
  5.16      143      1      0             0.7837    0.0296     0.7187    0.8354 
  5.29      142      1      0             0.7782    0.0299     0.7127    0.8305 
  5.39      141      0      1             0.7782    0.0299     0.7127    0.8305 
  5.49      140      0      1             0.7782    0.0299     0.7127    0.8305 
  5.62      139      2      0             0.7670    0.0305     0.7005    0.8206 
  5.65      137      0      1             0.7670    0.0305     0.7005    0.8206 
  5.85      136      0      1             0.7670    0.0305     0.7005    0.8206 
  5.95      135      0      1             0.7670    0.0305     0.7005    0.8206 
  6.02      134      1      0             0.7613    0.0308     0.6943    0.8156 
  6.08      133      0      1             0.7613    0.0308     0.6943    0.8156 
  6.15      132      0      1             0.7613    0.0308     0.6943    0.8156 
  6.18      131      1      0             0.7555    0.0311     0.6879    0.8104 
  6.51      130      1      0             0.7497    0.0314     0.6816    0.8052 
  6.71      129      1      0             0.7438    0.0317     0.6754    0.8000 
   7.1      128      1      0             0.7380    0.0320     0.6691    0.7948 
   7.3      127      1      0             0.7322    0.0323     0.6628    0.7896 





  7.33      126      2      0             0.7206    0.0328     0.6504    0.7791 
  7.53      124      0      1             0.7206    0.0328     0.6504    0.7791 
  7.66      123      1      0             0.7147    0.0330     0.6441    0.7738 
  7.69      122      1      0             0.7089    0.0333     0.6379    0.7685 
  7.86      121      2      0             0.6972    0.0338     0.6254    0.7578 
  7.92      119      0      1             0.6972    0.0338     0.6254    0.7578 
  7.96      118      0      1             0.6972    0.0338     0.6254    0.7578 
  8.38      117      1      0             0.6912    0.0340     0.6191    0.7524 
  8.48      116      0      1             0.6912    0.0340     0.6191    0.7524 
  8.55      115      0      1             0.6912    0.0340     0.6191    0.7524 
  8.71      114      1      0             0.6851    0.0342     0.6127    0.7469 
  8.81      113      2      0             0.6730    0.0347     0.5999    0.7358 
  8.88      111      1      0             0.6670    0.0349     0.5935    0.7302 
  9.57      110      1      0             0.6609    0.0351     0.5871    0.7246 
  9.93      109      1      0             0.6548    0.0353     0.5808    0.7190 
 10.19      108      1      0             0.6488    0.0355     0.5744    0.7134 
 10.29      107      0      1             0.6488    0.0355     0.5744    0.7134 
 10.65      106      1      0             0.6426    0.0357     0.5681    0.7077 
 10.75      105      0      1             0.6426    0.0357     0.5681    0.7077 
 10.78      104      0      1             0.6426    0.0357     0.5681    0.7077 
 10.88      103      1      0             0.6364    0.0359     0.5615    0.7019 
 11.08      102      1      0             0.6302    0.0361     0.5550    0.6961 
 11.28      101      1      0             0.6239    0.0362     0.5486    0.6903 
 11.44      100      1      0             0.6177    0.0364     0.5421    0.6845 
 11.51       99      0      1             0.6177    0.0364     0.5421    0.6845 
  11.7       98      1      0             0.6114    0.0366     0.5356    0.6786 
 11.84       97      1      0             0.6051    0.0367     0.5290    0.6727 
    12       96      1      0             0.5988    0.0369     0.5226    0.6668 
 12.39       95      1      0             0.5925    0.0370     0.5161    0.6609 
 12.46       94      0      1             0.5925    0.0370     0.5161    0.6609 
 12.89       93      0      1             0.5925    0.0370     0.5161    0.6609 
 12.92       92      0      1             0.5925    0.0370     0.5161    0.6609 
 13.45       91      1      1             0.5860    0.0372     0.5094    0.6548 
 13.61       89      0      1             0.5860    0.0372     0.5094    0.6548 
 13.87       88      1      0             0.5793    0.0374     0.5025    0.6485 
  14.4       87      1      0             0.5726    0.0375     0.4956    0.6423 
 14.47       86      0      1             0.5726    0.0375     0.4956    0.6423 
 15.06       85      0      2             0.5726    0.0375     0.4956    0.6423 
 15.32       83      1      0             0.5657    0.0377     0.4885    0.6358 
 15.35       82      1      0             0.5588    0.0379     0.4814    0.6293 
 15.55       81      1      0             0.5519    0.0380     0.4743    0.6228 
 15.68       80      0      1             0.5519    0.0380     0.4743    0.6228 
 15.75       79      1      1             0.5450    0.0382     0.4671    0.6162 
 15.81       77      0      1             0.5450    0.0382     0.4671    0.6162 
 15.98       76      0      1             0.5450    0.0382     0.4671    0.6162 
 16.31       75      0      1             0.5450    0.0382     0.4671    0.6162 
 16.34       74      0      1             0.5450    0.0382     0.4671    0.6162 
 16.47       73      1      0             0.5375    0.0384     0.4594    0.6092 
  16.5       72      0      2             0.5375    0.0384     0.4594    0.6092 
  16.6       70      0      1             0.5375    0.0384     0.4594    0.6092 
 16.83       69      0      1             0.5375    0.0384     0.4594    0.6092 
    17       68      0      1             0.5375    0.0384     0.4594    0.6092 
 17.33       67      1      0             0.5295    0.0386     0.4510    0.6018 
 17.56       66      0      1             0.5295    0.0386     0.4510    0.6018 
 17.95       65      0      1             0.5295    0.0386     0.4510    0.6018 
 18.44       64      1      0             0.5212    0.0389     0.4423    0.5942 
 18.51       63      1      1             0.5129    0.0392     0.4337    0.5865 
 18.81       61      1      0             0.5045    0.0394     0.4250    0.5787 
 19.23       60      0      1             0.5045    0.0394     0.4250    0.5787 
  19.4       59      0      1             0.5045    0.0394     0.4250    0.5787 
  19.5       58      0      2             0.5045    0.0394     0.4250    0.5787 
 19.96       56      0      1             0.5045    0.0394     0.4250    0.5787 
 20.15       55      1      0             0.4953    0.0397     0.4153    0.5703 
 20.38       54      1      0             0.4862    0.0401     0.4057    0.5619 
 20.42       53      1      0             0.4770    0.0403     0.3961    0.5534 
 20.48       52      0      1             0.4770    0.0403     0.3961    0.5534 
 20.55       51      0      1             0.4770    0.0403     0.3961    0.5534 
 22.32       50      0      1             0.4770    0.0403     0.3961    0.5534 
 22.98       49      1      0             0.4673    0.0407     0.3859    0.5444 
 23.51       48      0      1             0.4673    0.0407     0.3859    0.5444 





 23.97       47      0      2             0.4673    0.0407     0.3859    0.5444 
    24       45      0      1             0.4673    0.0407     0.3859    0.5444 
 24.56       44      0      1             0.4673    0.0407     0.3859    0.5444 
 24.99       43      0      1             0.4673    0.0407     0.3859    0.5444 
 25.08       42      1      0             0.4561    0.0412     0.3740    0.5345 
 25.97       41      0      1             0.4561    0.0412     0.3740    0.5345 
 26.14       40      1      0             0.4447    0.0417     0.3618    0.5242 
  26.5       39      0      1             0.4447    0.0417     0.3618    0.5242 
 26.76       38      0      1             0.4447    0.0417     0.3618    0.5242 
 26.93       37      0      1             0.4447    0.0417     0.3618    0.5242 
 27.42       36      0      1             0.4447    0.0417     0.3618    0.5242 
 27.48       35      0      1             0.4447    0.0417     0.3618    0.5242 
 27.72       34      0      1             0.4447    0.0417     0.3618    0.5242 
 28.14       33      0      1             0.4447    0.0417     0.3618    0.5242 
 28.41       32      1      0             0.4308    0.0427     0.3464    0.5124 
 30.15       31      0      1             0.4308    0.0427     0.3464    0.5124 
 30.51       30      0      1             0.4308    0.0427     0.3464    0.5124 
 30.67       29      1      0             0.4160    0.0437     0.3298    0.4998 
  31.4       28      0      1             0.4160    0.0437     0.3298    0.4998 
 31.53       27      1      0             0.4006    0.0447     0.3128    0.4866 
 33.07       26      0      1             0.4006    0.0447     0.3128    0.4866 
 33.99       25      0      1             0.4006    0.0447     0.3128    0.4866 
    36       24      2     22             0.3672    0.0468     0.2765    0.4581 
-------------------------------------------------------------------------------  





3.8.2 Figures: Plots of observed-versus-predicted survival curves 
 
A. Sex           
 
 
B. Seizure-free time          
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4.1 ABSTRACT  
 
4.1.1 Introduction. Neurocysticercosis is an infection of the human central nervous 
system by the cystic larval stage of the tapeworm Taenia solium. As part of their natural 
life cycle or subsequent to antihelmintic treatment, parenchymal brain cysts degenerate 
and resolve, either disappearing or leaving a small, calcified lesion in the host brain. 
Some of these patients will present seizures and subsequently epilepsy, needing 
symptomatic treatment with antiepileptic drugs (AED). After an appropriate seizure free 
period, these patients are candidates for AED withdrawal. Risk factors for seizure relapse 
after AED withdrawal in calcified NCC have not been adequately assessed. Departing 
from a cohort of patients with calcified NCC and epilepsy under AED treatment (n=202), 
a subgroup analysis was performed to evaluate the incidence rate and factors associated 
with seizure recurrence in patients who withdraw their AED treatment (n=62). 
 
4.1.2 Methods. This cohort study assessed data from participants of the parent cohort 
who withdrew their AED treatment. In the parent cohort, participants had a detailed 
history and clinical examination. During the follow-up, the study team carefully recorded 
dates and characteristics of seizure episodes, seizure-free periods, and date and reason of 
AED discontinuation. Patients were monitored by telephone every two-weeks and also 
were asked to attend a clinical visit at the study site every 3 months. They were also 
instructed to immediately report to the study team any seizure-related event. The study 
physician and neurologist confirmed the information and classified seizures according to 
the ILAE guidelines. Descriptive and survival analysis were performed using Kaplan-
Meier estimator and Cox regression.   
 
4.1.3 Results. Sixty two participants who withdrew AED were included in this 
observational cohort. Their mean age of participants was 38 years and there were slightly 
more females than males (34/28). Throughout a mean follow up time of 17.3 months, 17 
(27.4%) patients presented with seizure relapses. The cumulative survival incidence of 
seizure relapse was 41.4% along a maximum of 36 months of follow-up. Nearly half of 





this observational cohort (31/62) had less than 2 years seizure-free before AED 
withdrawal, and almost all patients who had seizure relapses (15/17) belong to this group 
of participants. Cox regression models of the entire cohort showed that the main risk 
factors were having seizures in the last two years before AED withdrawal (HR 9.21 
95%IC 2.22-38.04 p= 0.002). We only selected this subgroup of 31 participants for 
subsequent analysis. We found that having a history of ten or more seizures and having 
had at least a generalized seizure or focal seizure with generalization show a trend of 
increased risk of seizure relapse but without statistical significance. Participants prone to 
withdraw the AED are young people, participants with history of only focal seizures, free 
of seizures in the prior year to enrollment, and participants with a weak serum reaction to 
EITB-WB.  
  
4.1.4 Conclusion. We recommend that patients with calcified NCC achieve at least 2 
years seizure-free and adhere to standard guidelines to be considered ready for AED 
withdrawal. Additionally, patients with a history of ten or more seizures, generalized 









4.2 INTRODUCTION  
 
Neurocysticercosis (NCC), defined as the infection of the central nervous system 
(CNS) by the larval stage of the zoonotic tapeworm Taenia solium, remains a major 
challenge in public health due to associated secondary epilepsy.
1-3
 It has been 
consistently demonstrated that NCC is one of the leading cause of acquired epilepsy in 
endemic countries,
5-8
 and likely worldwide; in fact, approximately 80% of the disease 
burden caused by epilepsy is located in developing countries.
4, 207
   
 
T. solium larvae lodge in the brain parenchyma as viable cysts. At the end of their 
natural life cycle or subsequent to antiparasitic treatment, these cysts degenerate and a 
portion of these lesions progress to a residual parenchymal calcified lesion.
13
  Cerebral 
calcifications persist in the host brain permanently, and in endemic areas, calcifications 





There is consensus in the literature that an individualized approach to the 
discontinuation of AED in PWE is needed considering the main risk factors:
209, 210
 older 
age at seizure onset, longer duration of epilepsy disease, abnormal neurological 
examination or psychiatric findings, abnormal EEG findings, increased number of 
seizures during AED therapy or history of status  epilepticus, greater number of AED 
used during treatment, and failure in previous withdrawal attempts.
148, 211, 212
 
Additionally, gradual AED withdrawal is also recommended.
145, 210, 213, 214
 
 
Recommendations for AED withdrawal in patients with epilepsy and NCC have 
never been systematically assessed and are mostly based on expert opinion.
215
 Most 
studies in NCC that report risk factors for seizure relapse after AED withdrawal have 
been done in NCC patients with mixed NCC (viable, degenerating, and/or calcified) 
29, 41
  
and in patients with a single enhancing lesion.
152-156, 166
 Risk factors in these studies, 
besides the presence of residual calcifications, are having recurrent or multiple seizures, 





abnormal interictal EEG, and seizures events that occurred under AED treatment.  In 
calcified NCC, only three small studies have reported seizure relapse after AED 




In a cohort of patients with epilepsy due to calcified NCC under AED drug 
(n=202) we found that control of seizures is suboptimal, survival analysis showed that 
only 36% remains free of seizure after a follow-up of 3 years. Main risk factors for 
breakthrough seizure were having had a seizure within one year before enrollment, a 
history of ten or more seizures, and having an abnormal inter-ictal EEG (Chapter 3).  
This current study was performed in patients belonging to this cohort in whom AED 
treatment was interrupted (n=62) and is aimed to evaluate the incidence rate of seizure 
relapse after AED withdrawal and its associated risk factors.   
  






4.3 MATERIAL AND METHODS  
 
4.3.1 Study Design. This is a prospective cohort study to explore risk factors for 
incidence of seizure recurrence and associated risk factors in epileptic patients with 
calcified NCC who withdrew their AED treatment.  
 
4.3.2 Study Population and selection criteria. Departing from a cohort study of 
approximately 202 patients with calcified NCC under AED treatment, we identified a 
sub-group of 62 patients who had withdrawn their AED treatment in order to evaluate 
their seizure relapse and risk factors. Selection criteria for the parent cohort included: 
male or female participants between 12-75 years of age, epilepsy secondary to NCC, and 
calcified NCC as determined by CT scan. Participants with abnormal paroxistic EEG, 
viable or degenerating NCC lesions, positive parasite antigen test, intracranial 
hypertension, hydrocephalus, or focal neurological deficits were excluded.  
 
4.3.3 Study Activities. We included patients with calcified NCC under AED who were 
already under follow-up as part of a cohort who did stop their AED treatment. In the 
parent cohort, participants had a detailed history and clinical examination where they 
provided clinical information regarding seizure history (months since first seizure, 
seizure-free months before enrollment, number of previous seizures, description of 
seizures, and family history of seizures). All this information was updated considering the 
day when the participant withdrew their AED as the date of enrollment. Also we 
considered previously recorded information such as previous courses of antiparasitic 
treatment as well as topographic location and size of calcified lesions in brain CT scan 
images. At the time of enrollment in this cohort (patients who stopped their AED 
treatment), we did not perform an additional EEG,  serum EITB,
55
 or ELISA for antigen 
detection.
183
 We used the results obtained for these tests at entry to the parent cohort for 
our analysis.     
 





4.3.4 Follow-up.    We carefully recorded dates and characteristics of seizure episodes, 
seizure-free periods, and day and reason of AED discontinuation. Patients in this cohort 
were closely followed to monitor seizure relapse from AED discontinuation for 36 month 
after enrollment (or until November 2017). They were asked to visit the clinical site 
every 3 months for follow up and instructed to immediately report to the study team any 
event compatible with a seizure. They were also monitored by telephone every 2 weeks 
by the study team. A diagnosis of seizures was initially made by interview with the 
patient or witnesses of the event; the information was verified by the study physician and 
study neurologist. All seizure events were classified according the 2010 ILAE 
guideline.
105
 The new epilepsy classification according to ILAE 2017
106
 did not change 
the seizure classification made in this study. The attending neurologist was responsible 
for medical care if participants presented with seizure activity during the follow-up. The 
study team provided the attending neurologist with all clinical information and test results 
obtained as part of this study.       
 
4.3.5 Outcome Assessment.  Our main outcome was the presence of seizure relapses 
after AED withdrawal. Seizure dates were recorded to assess the cumulative incidence, 
incidence rate, and to perform a time-to-event analysis, which considered the time period 
since AED withdrawal until event (seizure relapse), lost to follow-up, or censoring, to 
calculate the survival curve free of seizure and the hazard ratio. 
 
4.3.6 Covariates.  We evaluated the following covariates: age in years (continuous 
variable and also as categories using tertiles), sex (female/male), previous antiparasitic 
treatment for viable neurocysticercosis (yes/no), months since first seizure (discrete 
variable and also as dichotomous using >36 months), seizure-free months before 
enrollment (discrete variable and also as dichotomous variable using >24 months), 
number of previous seizures (discrete variable and also dichotomous variable using >10 
seizures), family (first-degree relatives) history of seizures (yes/no), a history of type of 
seizures (focal seizures /generalized seizure or focal seizure with generalization), EITB 
result (≤3 reactive antibody bands/≥4 reactive bands), tapering at AED withdrawal 
(yes/no), number of calcifications (discrete variable and also as categories 1/2-10/>10), 





and topographic location of calcifications according to cerebral lobes: frontal/other, 
parietal/other, occipital/other, and temporal/other. (Table 4.7.1) All variables involving 
time measurement were considered in relation to the date of AED withdrawal.  
 
4.3.7 Statistical analysis. To characterize the population, descriptive information was 
presented using summary statistics. Categorical variables were expressed as proportions, 
whereas continuous and discrete variables were expressed using mean ± standard 
deviation or median and ranges respectively. Overall frequency of seizure relapse was 
reported with 95% confidence intervals, and compared by covariates using two-sample 
parametric or non-parametric tests as appropriate to variable. For the survival analysis the 
following criteria were applied:  event - seizure reported by the patient and confirmed by 
the study physician , time origin - date when patient completed AED withdrawal, time 
metric – duration of follow-up in months up to event, administrative censoring (36 
months of follow-up or predefined date: November 30, 2017), re-starting of AED, or lost 
to follow-up. We employed bivariate Cox regression analysis to evaluate hazard risk. We 
also used the survival Kaplan-Meier estimator and log-rank test method to assess 
cumulative event-free survival curve with confidence interval of 95%. Predicted survival 
functions after Cox regression were also plotted. Additionally, we explored variables 
associated with AED withdrawal using bivariate analysis and multivariate analysis with a 
log-binomial regression model. All statistical analyses were done using Stata/IC 15.0 
(Stata Corp, College Station, TX, US). 
 
4.3.8 Human subjects rights protection. The study was reviewed and approved by the 
UPCH IRB and by the IRB of the National Institute of Neurological Sciences both in 
Lima, Peru. All study personnel who had contact with subjects or data, completed a 
course on human subject protection.  
  






4.4 RESULTS  
 
From 202 participants with epilepsy, calcified NCC and AED treatment in the 
parent cohort, 62 patients stopped their antiepileptic treatment and were included in this 
study. This prospective cohort was carried out from July 2012 to November 2017.  The 
main characteristics of these 62 patients are presented in Table 4.7.1. The mean age of 
patients was 38.1 ± 13.2 years, and the proportion of females was slightly higher (54.8%,  
34/62) than males. Thirty-nine (62.9%, 39/62) patients had a history of antiparasitic 
treatment for NCC, the median time with seizures was 96 months (IQR: 53-195), the 
median number of previous seizures was 9 (IQR: 3-21), the median seizure-free time 
before enrollment was 24 months (IQR: 6-59), and most cases (72.6% [45/62]) reported 
at least one generalized seizure or a focal seizure with generalization. Seven patients 
(11.3% [7/62]) had a family history of seizures, and ten patients (16.1% [10/62]) had an 
EITB result ≥4 bands. The participants had a median of four (IQR: 1-9) calcifications, 
and lesions were more frequently located in the frontal lobes (77.4%) than in other lobes. 
 
In a mean follow up time of 17.3 months after AED withdrawal, 17 (27.4% ± 
13.2) patients presented with seizure relapses. The strongest risk factor for seizure relapse 
was the length of time free of seizures at the time of AED discontinuation. Only 6.5% 
(2/31) of people who were seizure free for more than 2 years presented a seizure relapse, 
compared to 48.4% (15/31) of people who had at least one seizure in the previous 2 years 
before AED withdrawal (p<0.001). Participants with a history of ten or more seizures had 
more seizure relapses (40.7% [11/27] versus 17.1% [6/35], p=0.039). A shorter time of 
disease ( 36 months) was a marginal risk factor for seizure relapse (57.1% [4/7] versus 
23.6% [13/55], p=0.061). Other characteristics were not significantly different between 
patients who presented seizure relapses or not during the study (Table 4.7.1).  
 
Survival analysis showed 17 patients who had seizure relapse in a total analysis 
time of 1,071.3 months at risk with a median time per subject of 17.52 months (IQR: 7.9-





20.9 months), to an incidence rate of 15.9 events per 1,000 patient-month. The Kaplan-
Meier estimator showed that the probability of being seizure-free after 3 years of AED 
withdrawal is was 58.7% (95% CI: 38.3%-74.31%) (Figure 4.7.1 and Supplementary 
Information 4.8.1).  
 
The standard of care recommends at least 24 months seizure-free to retire the 
AED; in our cohort, 15 out of 17 events were observed in participants with less than 24 
months free of seizures (Figure 4.7.2), and the time-to-event evaluation using univariate 
Cox analysis showed that these participants had 9.2 times the risk of having an seizure 
relapse (HR 9.21, 95% IC 2.22-38.04, p=0.002). This group, participants with less than 
two years free of seizures include 31 out of 62 patients of the entire cohort (Table 4.7.1).   
 
These 31 participants with less than 24 months free of seizures did not presented 
an additional statistically significant risk factor, probably due to small number of 
participants. Nevertheless, we found that having a history of ten or more seizures before 
AED increased the risk of seizure relapse (HR 1.96, 95%IC 0.66-5.79, p=0.220). Also, 
participants with a history of partial seizures with generalization or generalized seizures 
had a higher risk of having a seizure relapse, but without statistical significance (HR 
2.19, 95%IC 0.48-9.88, p=0.306, Table 4.7.2). 
 
None of the other variables: age, sex, antecedent of antiparasitic treatment, family 
antecedent of seizure, a positive cysticercosis EITB-LLGP serology (≥ 4 bands), number 
or location of calcifications, age of onset of epilepsy, gradual tapering of AED or time 
with seizures were associated with a higher risk of new seizures after AED withdrawal. 
 
We evaluated variables related to AED withdrawal (Tables 4.7.3 and 4.7.4).  
From the 202 participants in the main cohort, 62 of them stopped treatment. We 
compared these participants who ended AED treatment (due to medical indication [42], 
self-decision [18], and unknown causes [2]) with those who continued medication (140). 
We found, in the adjusted model, that the participants who were seizure-free for more 
than one year were 1.6 times more likely to withdraw from the antiepileptic treatment 





(1.60 95%IC 1.05-2.39, p=0.014).  On the other hand, patients who were older than 28 
years (29y-40y RR 0.56 95%IC 0.33-0.92, p=0.024 and >40y RR 0.69 95%IC 0.43-1.12, 
p=0.138), had a history of generalized seizures or focal seizure with generalization (RR 
0.59 IC95% 0.38-0.91, p=0.019), or had more than three bands in their EITB-WB result 
(RR 0.56 IC95% 0.32-1.00, p=0.052), were less likely to stop their antiepileptic 
treatment. 
  






4.5 DISSCUSSION  
 
Our study demonstrates that a significant proportion of patients with epilepsy 
secondary to NCC who withdraw AED therapy will have seizure relapses, mostly due to 
premature interruption of AEDs. Over a median follow-up period time of 17.5 months, 
the cumulative incidence of seizure relapse was 27.4% (17/62). The incidence rate was 
15.9 events per 1,000 patient-months, and survival analysis showed a cumulative hazard 
of seizure relapse of 42.3% in a maximum of 36 months of follow up.  
 
Half of our cohort (31 patients) stopped their AED treatment before achieving 2 
years seizure-free, and almost all cases with seizure relapses (15 out of 17, (88.2%) 
occurred in these patients. Withdrawing AEDs before 24 months seizure free was 
associated with a 9 times higher risk of seizure relapse on univariate time-to-event 
analysis (HR 9.21 95%IC 2.22-38.04, p=002), making it evident that the standard 
recommendation of 2 years seizure free before discontinuing AED therapy should be 
appropriately followed in patients with calcified NCC.  In this high risk subgroup 
(individuals who withdrew AEDS before achieving 2 years seizure free), there was 
around twice the risk for relapse if they had a history of ten or more seizures before AED 
withdrawal and a history of partial seizures with generalization or generalized seizures, 
although none of these associations reached statistical significance.  
 
In contrast, only 6.5% (2/31) of patients who had been seizure-free in the previous 
2 years after antiparasitic withdrawal presented with a seizure relapse. This low 
proportion is strikingly different from the scarce reports of seizure relapse after AED 
withdrawal in calcified NCC. Only three studies evaluated this risk prospectively.
29-31
 
The cumulative incidence of seizure relapse was over 80% in these studies in the first 




 and 100% [8/8] 
31
). Many potential reasons could contribute to this evident discrepancy. Unlike prior 
studies, our cases were systematically included as part of a much larger cohort and likely 





included cases with milder epilepsies (the extremely high rates of seizure relapse in older 
studies suggest a bias towards more severe clinical disease). We also ruled out viable or 
degenerating NCC lesions using MRI and CT, as well as the serological assays of choice 
(LLGP-EITB for antibody detection, and monoclonal antibody-based ELISA for the 
detection of circulating parasite antigen). Finally, we had a very close follow up of cohort 
patients, likely encouraging better compliance with drug treatment and risk avoidance. In 
these well-defined patients with pure calcified NCC who have achieved 2 years free of 
seizures, adding additional months or years of AED treatment may not be indicated and 
conversely may unnecessarily expose them to adverse events, impact in their quality of 
life, and cause significant direct and indirect economical costs. 
 
In other epilepsies, the cumulative incidence of seizure relapse in adults who 
withdraw their AED after 2 years free of seizures are higher than our results and ranges 
from 15% to 32% and from 29% to 43% at 1 or 2 years of follow-up after AED 
withdrawal respectively.
143, 147, 149-151, 216
  On the other hand, studies in patients with 
single enhancing lesions (SEL) with 2 years free of seizure presented similarly low 
cumulative incidence of seizure relapses at 12 to 18 months of follow-up (12% or less 
[5.8% 3/51,
153
 11.5%  30/26,
155




The standard approach to AED tapering considers at least 2 years seizure free,
145, 
209, 210, 213, 214
 in addition to assessing the most common causes of seizure relapse. This 
risk factors include older age at seizure onset, longer duration of epilepsy disease, 
abnormal neurological or psychiatric findings, abnormal EEG findings, increased number 
of seizures during AED therapy, history of status epilepticus, or greater number of AEDs 




As in the parent cohort of patients under AED treatment, having a history of ten 
or more prior seizure episodes seems to be a predictor of seizure relapse. In the univariate 
model, people with this condition have almost double the chance of having a seizure 
relapse in the following 3 years after AED withdrawal but without statistical significance.  
This variable was not evaluated in the previous three studies in calcified NCC published 









   However, in patients with epilepsy caused by 
other etiologies than NCC, it has been consistently reported that having had multiple 
seizure events is a prognostic factor for seizure relapse after AED withdrawal, probably 
because epileptogenic circuits have been already established.
145
   
 
Patients having a history of generalized seizures or focal seizures with 
generalization also had almost two-times the chance of having a seizure relapse in the 
following 3 years in univariate time to event analysis but without statistical significance, 
probably due to the small sample size. A history of generalized seizures, in patients with 
epilepsy caused by other pathologies than NCC, has also been consistently reported as 




Having received antiparasitic treatment was not associated with increased risks of 
seizure relapse after AED withdrawal. This finding is consistent with previous studies in 
calcified NCC published by Del Brutto et al.,
30
  and Nash et al.
28
 Data from the overall 
parent cohort (Chapter 3), as well as other studies, are consistent with this finding, 
supporting the fact that antiparasitic treatment does not result in an increased risk of 
seizure events in the long term.
25, 26, 71, 72, 203-205
  
 
A number of variables were not associated with the risk of seizure relapses, 
including age, sex, strength of the antibody response, and less intuitively, breakthrough 
seizures, and number or location of parasitic brain lesions. Seizure events during the 
AED treatment has been consistently pointed out as risk factor for seizure relapse after 
AED withdrawal however in this cohort this variable was not a risk factor for seizure 
recurrence.  
 
Variables related to AED withdrawal in our cohort under AED treatment were 
also evaluated. Identification of these variables may help physicians and patients make 
more refined decisions on whether or not to stop antiepileptic treatment. We found four 
variables related to continuation of the antiepileptic drug, and all of them were associated 
with disease consciousness. Patients were more likely to continue AED treatment if they 





were older (>28 years), had at least one seizure one year before enrollment (in the parent 
cohort), had a history of generalized seizure or focal seizure with generalization, and had 
strong positive test results from the EITB-Western Blot (more than three bands). 
Interestingly, the number of calcifications or the number of previous seizures was not 
related to the decision for antiepileptic treatment withdrawal.  
 
Our study has some evident weaknesses, in particular the small number of 
participants that affects the statistical significance and precluded the use of a multivariate 
model of analysis. Since clinical patient care was managed by the attending neurologists 
and was not part of the observational cohort procedures, variable criteria were applied to 
indicate AED withdrawal, in some cases without EEG tracings before tapering drug 
coverage. Seizure characterization was likely suboptimal, based on patient interviews and 
interviews with relatives and witnesses without video-EEG support. We did not perform 
a new serology before AED withdrawal. Thus, our analysis of this variable only 
considered the serology result at entry to the preceding cohort.  Our study cohort 
incorporated patients systematically included from a larger cohort of patients with 
calcified NCC as they withdrew AEDs (increasing their representativity) but at the same 
time, the parent cohort was assembled in a neurological reference center, and as such, 
they may not be representative of all patients with NCC. Finally, the quality of our 
seizure data may be affected by recall bias, indirect source of information (witnesses of 
seizures with generalization), and misclassification arising from the fact that the study 
physician was not masked to the radiological or clinical information and may therefore 
have over- or under-diagnosed seizure relapses.  
 
AED withdrawal has several benefits including prevention of side effects such as 
cognitive impairment or possible teratogenic effects, improvement of quality of life, 
reduction of direct and indirect economic costs, reduction of stigma, and elimination of 
potential drug interaction.
143
  Nevertheless, AED withdrawal can result in seizure 
relapse.
144
  In patients with calcified NCC, gradual withdrawal of AEDs should be 
considered only in patients with at least 2 years free of seizures. Some authors advocate 





for early AED withdrawal,
218, 219
 According to our data, this advice is evidently 
contraindicated for patients with calcified NCC and epilepsy.  
  








Patients with calcified NCC and epilepsy should follow the standard of care 
recommendation and complete at least 2 years free of epilepsy before gradual AED 
retirement. On the other hand, adding further months or years of AED treatment after 2 
years free of seizures may not be indicated given the low likelihood of seizure relapse, 
less than 10% (2/31), and additional treatment could expose those patients to undesired 














Table 4.7.1. Demographic, clinical and neuroimaging characteristics of the study cohort 
(N=62), and bivariate analysis by seizure relapse.  
 
Characteristics  n (%) 
Seizure relapse 
Yes (N=17) No (N=45) p  
value  n (%) n (%) 
Age (years) 
    Mean ± SD 
 
38.1 ± 13.2 
 
37.8 ± 13.3 
 
38.2 ± 13.3 
 
0.914 
Sex (Female) 34 (54.8%) 10 (58.8%) 24 (53.3%) 0.698 
Previous APT (yes) 39 (62.9%) 10 (58.8%) 29 (64.4%) 0.683 
Seizure time (months) 
    Median (IQR) 













Number of previous seizures     
    Median (IQR) 













Seizure-free time before 
enrollment (months) 
    Median (IQR) 

















Family history of seizures  7 (11.3%) 3 (17.65%) 4 (8.9%) 0.331 
Generalized and/or focal partial 
seizures with generalization 
45 (72.6%) 14 (82.4%) 31 (68.9%) 0.289 
EITB result ≥4 bands* 10 (16.1%) 2 (11.1%) 8 (17.8%) 0.566 




23 (43.4%) 6 (40.0%) 17 (44.7%) 0.754 
Number of calcifications 
    Median (IQR) 
    Single calcifications 
    2 to 10 calcifications 





















Location of calcifications 
    Frontal lobe 
    Parietal lobe 
    Occipital lobe 






















Abbreviations: Standard deviation (SD), antiparasitic treatment (APT), interquartile range (IQR), enzyme-like 
immunoelectrotransfer blot (EITB), electroencephalogram (EEG), antiepileptic drug (AED),  not determined 
(ND).  
Data at the time of AED withdraw is presented, except in cases marked with (*) where data come from the 
time of entry to the parent cohort    
Bold values are considered statistically significant (p<0.05). 
a
Three observations were missed 
b









Table 4.7.2 Descriptive and Univariate Cox proportional-hazard regression model to 
assess potential risk factors for seizure relapse during follow-up in patients who did not 
achieve two years seizure-free time before withdrew their AED.  
 
Variables 












         ≤28 years  
         29-40 years 


















          Male  














          Yes   














         >36 months  













Number of previous seizures 
         ≤10 seizures  













Family history of seizures 
         No  













Generalized and/or focal 
seizures with generalization 
    No 

















EITB positive to ≥ 4bands* 
    Positive  













AED withdrawal with gradual 
taper
a
               
                                              Yes 

















Number of calcifications 
    Single calcifications 
    2 to 10 calcifications 

















Location of calcifications  
    Frontal lobe 
    Parietal lobe 
    Occipital lobe 





















Abbreviations: Standard deviation (SD), antiparasitic treatment (APT), interquartile range (IQR), enzyme-like 
immunoelectrotransfer blot (EITB), antiepileptic drug (AED),  not determined (ND).  
Data at the time of AED withdraw is presented, except in cases marked with (*) where data come from the 
time of entry to the parent cohort    
a
One observations were missed  





Table 4.7.3. Demographic, clinical and neuroimaging characteristics of the patients 
belonging to the parent study cohort (N=202), and bivariate analysis by AED withdrawal. 
 
Variables                            
AED Withdrawal 





    Mean ± SD  
    ≤28 years 
    29-40 years 
    >40 years 
 
36.0 ± 13.2 
25 (40.3 %) 
 17 (27.42 %) 
20 (32.3 %) 
 
36.7 ± 29 
42 (30.0 %) 
55 (39.3 %) 






Sex (male) 28 (45.2 %) 72 (51.4 %) 0.411 
Previous APT (yes) 39 (62.9 %) 93 (66.43 %) 0.627 
Seizure time prior to  
stopping AED (months)   
    Median (IQR)  













Seizure-free time prior to  
stopping AED (months) 
    Median (IQR) 













Number of previous seizuresa 
    Median (IQR) 










Family history of seizures 7(11.3) 19(13.6) 0.655 
Generalized and/or focal 
seizures with generalization 
46 (74.2 %) 119 (85.0 %) 0.067 
EITB result ≥4 bands 10 (16.3 %) 40 (28.6 %) 0.059 
Perilesional Edemac  12 (32.4 %) 50 (30.3 %) 0.800 
Large calcificationsc 4 (33.3 %) 58 (30.5 %) 0.838 
Number of calcifications 
    Median (range) 
    Single calcification 
    2 to 10 calcifications 
    >10 calcifications 
 
4 (1-19) 
19 (30.7 %) 
29 (46.8 %) 
14 (22.6 %) 
 
2 (1-12) 
47 (33.6 %) 
56 (40.0 %) 






Location of calcifications 
    Frontal lobe 
    Parietal lobe 
    Occipital lobe 
    Temporal lobe 
 
48 (77.4 %) 
35 (56.5 %) 
20 (32.3 %) 
29 (46.8 %) 
 
112 (80.0 %) 
76 (54.3 %) 
61 (43.6 %) 







Standard deviation (SD), interquartile range (IQR), antiparasitic treatment (APT),  
enzyme-linked immunoelectrotransfer blot  (EITB). 
Bold values are considered statistically significant (p<0.05).  
a 
One observation was missed.  
c 
At least one calcified lesion   





Table 4.7.4 Baseline risk factors for antiepileptic drug withdrawal in patients with 
calcified NCC and epilepsy (n=202)  
 
Variables 
Univariate models Adjusted model  
RR (95%CI) p value RR (95% CI) p value 





























Seizure time                         ≤36 months 






Seizure-free time before 




























Generalized and/or focal seizures 
























Number of calcifications             Single 









Perilesional Edema c                         No 






Large calcifications c                        No 































*Patients with an abnormal EEG result were excluded for the analyses 
Confidence interval (CI), antiparasitic treatment (APT), enzyme-linked immunoelectrotransfer blot 
(EITB), and electro encephalogram (EEG).  
Bold p values are statistically significant 
a 
One observation was missed.  
c 














Figure 4.7.1 Kaplan-Meier plot of seizure relapse in patients who stopped their AED 
  
 
Figure 4.7.2 Survival curve by seizure-free time before AED withdrawal 
 







4.8.1 Table Kaplan-Meier Survival Probability Estimates  
 
           Beg.          Net            Survivor      Std. 
  Time    Total   Fail   Lost           Function     Error     [95% Conf. Int.] 
------------------------------------------------------------------------------- 
 .1973       62      1      0             0.9839    0.0160     0.8910    0.9977 
 1.019       61      2      0             0.9516    0.0273     0.8574    0.9841 
 1.052       59      1      0             0.9355    0.0312     0.8372    0.9753 
 1.381       58      0      1             0.9355    0.0312     0.8372    0.9753 
  2.17       57      0      1             0.9355    0.0312     0.8372    0.9753 
 2.433       56      1      0             0.9188    0.0348     0.8158    0.9654 
 2.466       55      1      0             0.9021    0.0380     0.7949    0.9548 
 3.847       54      0      1             0.9021    0.0380     0.7949    0.9548 
 3.912       53      0      1             0.9021    0.0380     0.7949    0.9548 
 4.175       52      0      1             0.9021    0.0380     0.7949    0.9548 
 4.767       51      1      0             0.8844    0.0412     0.7725    0.9432 
 4.899       50      0      1             0.8844    0.0412     0.7725    0.9432 
  5.26       49      1      0             0.8663    0.0441     0.7501    0.9309 
 7.134       48      1      0             0.8483    0.0467     0.7282    0.9182 
 7.956       47      0      1             0.8483    0.0467     0.7282    0.9182 
 8.153       46      0      1             0.8483    0.0467     0.7282    0.9182 
 8.778       45      0      1             0.8483    0.0467     0.7282    0.9182 
 9.995       44      1      0             0.8290    0.0495     0.7047    0.9044 
 10.68       43      0      1             0.8290    0.0495     0.7047    0.9044 
 10.78       42      0      1             0.8290    0.0495     0.7047    0.9044 
 11.08       41      0      1             0.8290    0.0495     0.7047    0.9044 
 11.34       40      0      1             0.8290    0.0495     0.7047    0.9044 
 12.39       39      0      1             0.8290    0.0495     0.7047    0.9044 
 12.89       38      0      1             0.8290    0.0495     0.7047    0.9044 
 12.99       37      1      0             0.8066    0.0530     0.6762    0.8886 
 13.12       36      0      1             0.8066    0.0530     0.6762    0.8886 
 14.27       35      1      0             0.7836    0.0563     0.6477    0.8720 
 14.56       34      0      1             0.7836    0.0563     0.6477    0.8720 
 15.88       33      0      1             0.7836    0.0563     0.6477    0.8720 
 17.52       32      0      2             0.7836    0.0563     0.6477    0.8720 
 17.92       30      0      1             0.7836    0.0563     0.6477    0.8720 
 18.08       29      1      0             0.7565    0.0605     0.6132    0.8529 
 18.77       28      0      1             0.7565    0.0605     0.6132    0.8529 
 20.05       27      1      0             0.7285    0.0644     0.5785    0.8325 
 20.12       26      0      1             0.7285    0.0644     0.5785    0.8325 
 20.45       25      0      1             0.7285    0.0644     0.5785    0.8325 
 20.94       24      1      1             0.6982    0.0685     0.5414    0.8102 
 20.98       22      0      1             0.6982    0.0685     0.5414    0.8102 
 21.21       21      0      1             0.6982    0.0685     0.5414    0.8102 
 22.13       20      0      1             0.6982    0.0685     0.5414    0.8102 
 23.24       19      0      1             0.6982    0.0685     0.5414    0.8102 
 23.28       18      0      1             0.6982    0.0685     0.5414    0.8102 
 23.31       17      0      1             0.6982    0.0685     0.5414    0.8102 
 26.33       16      0      1             0.6982    0.0685     0.5414    0.8102 
 26.86       15      1      0             0.6516    0.0781     0.4764    0.7808 
 27.22       14      0      1             0.6516    0.0781     0.4764    0.7808 
 27.32       13      0      2             0.6516    0.0781     0.4764    0.7808 
 31.96       11      0      1             0.6516    0.0781     0.4764    0.7808 
 34.09       10      1      0             0.5865    0.0936     0.3832    0.7431 
 35.21        9      0      1             0.5865    0.0936     0.3832    0.7431 










4.8.2 Table  Cox proportional-hazard regression models to assess potential risk factors 
















         ≤28 years  
         29-40 years 
         >40 years 
 









          Male  
          Female 
 







          Yes   
          No 
 







         >36 months  
         ≤36 months 
 
     1.00 










Seizure-free time before 
enrollment 
         >24 months  
         ≤24 months  
 
      1.00 





    1.00 




Number of previous seizures 
         ≤10 seizures  
         >10 seizures 
 
      1.00 





    1.00 




Family history of seizures 
         No  
         Yes 
 
      1.00 





Generalized and/or focal 
seizures with generalization 
    No 
    Yes 
 
 
      1.00 







    1.00 





EITB positive to ≥ 4bands 
    Positive  
Negative     
 
      1.00 





AED withdrawal with gradual 
taper
b
               
                                             Yes 
    No 
   
 
      1.00 






Number of calcifications 
    Single calcifications 
    2 to 10 calcifications 
    >10 calcifications 
 








Location of calcifications  
    Frontal lobe 
    Parietal lobe 
    Occipital lobe 











    2.80 (0.73-10.63) 0.134 
Abbreviations: Confidence intervals (CI), antiparasitic treatment (APT), enzyme-linked 
immunoelectrotransfer blot (EITB), antiepileptic drug (AED)  
a
Multivariate model was fitted using covariates with a p <0.200 from Wald test in univariate analysis.  
b
Three observations were missed   






4.8.3 Table. Schoenfeld’s residual test to assess the proportional hazards assumption for 







Rho p value 
Seizure time (≤36 months) 0.0152 0.955 
Number of previous seizures (>10) 0.1121 0.667 
Seizure-free time before enrollment (≤24 
months) 
-0.4975 0.050 
Generalized and/or partial seizures with 
secondary generalization 
0.1644 0.525 
Calcified lesions in temporal lobe 0.2896 0.175 
Global test  0.279 
 
  









4.8.5 Figure. Survival curve by time of disease (seizures) AED withdrawal 
 





4.8.6 Figure. Observed versus predicted survival curves plot for each of the variables 
included in the multivariate Cox proportional-hazard regression model in the entire 
cohort 















































CONCLUSION AND RECOMMENDATIONS 
 
Neurocysticercosis is still considered a major cause of acquired epilepsy in 
endemic countries, consistently around 30% of the secondary epilepsy is attributable to T. 
solium cysticercosis.
5, 6, 8
   NCC-associated epilepsy is a public health problem in 
developed countries mainly due to travel and migration.
12, 220, 221
. According the WHO 
almost 80% of the people with epilepsy live in low and middle income countries, thus 
NCC is one of the leading contributors of secondary epilepsy worldwide.
222
 Additionally, 
the T. solium zoonosis is the foodborne parasite causing the highest global burden and 





Parasites contained in viable cysts in the brain parenchyma eventually die due to 
natural life cycle or because of antiparasitic treatment; some of the cysts resolve, but 
others persist as small calcified lesions.
164
 Some of these patients with calcified scars will 
develop acute seizure and epilepsy.  There is abundant evidence in the literature 
supporting the hypothesis that cysts that evolve to calcified lesion are more prone to 




Understanding the cumulative incidence and risk factors for calcification (study 
1), subsequent breakthrough seizure during AED treatment (study 2), and seizure relapse 
after AED withdrawal (study 3) would provide important information to implement an 
individualized treatment approach. It would also potentially decrease the calcification 
process (study 1) and offer a better management of epilepsy, thus reducing the burden of 
the disease caused by epilepsy due to calcified NCC (Study 2 and 3).      
 
  





5.1 SUMMARY OF MAJOR FINDINGS 
 
5.1.1 Paper 1.  
The first study showed that 37.8% (188/497) of viable brain parenchymal 
cysts result in residual calcification one year after antiparasitic treatment. The risk 
factors for calcification at cyst level are large size of cysts (≥14 mm of diameter) 
and cysts with perilesional edema prior to antiparasitic treatment. At the patient 
level, we found as risk factors: longer duration of disease (more than 24 months 
of epilepsy), mild immunologic reaction as measured by EITB before antiparasitic 
treatment (less than four parasite proteins recognized by antibodies), use of an 
enhanced doses of ABZ (1.5 times), use of lower corticosteroid doses (≤6 mg/d), 
and lack of antiparasitic re-treatment after the first round of treatment among 
those with incomplete cyst cure. Thus, use of combined antiparasitic drugs, early 
antiparasitic re-treatment, and use of enhanced doses of corticosteroids would 
reduce or avoid calcification after antiparasitic treatment and potentially reduce 
future seizure recurrence. 
 
5.1.2 Paper 2.  
This cohort study involved 210 participants with epilepsy and calcified 
NCC. Almost 50% (103/210) presented with BTS during the follow-up. The 
Kaplan-Meier estimator showed that only 36% (95% CI: 27.2%-44.9%) remained 
free of seizures during a maximum of 3 years follow-up. Most of the events 
occurred within the first 2 years of follow-up (94/103). We found that having an 
abnormal interictal EEG was a main predictor of BTS (6 out of 8), and most the 
events were observed within the first 6 months (5 out of 6). Given the very high 
risk of these eight participants, they were excluded from further analysis. In the 
univariate and multivariate analysis we found two main predictors of BTS: having 
a history of ten or more seizures (HR: 2.91 p<0.001 and HR: 2.69 p<0.001 
respectively) and having at least one seizure event within the previous year prior 
to enrollment (HR: 1.77, p=0.006 and HR 1.55 p= 0.038 respectively). 






5.1.3 Paper 3 
This cohort was composed of 62 participants who withdrew their AED. 
Seventeen (24.7%) participants presented with seizure relapses; the cumulative 
incidence was 41.4% along a maximum follow up of 36 months. Half of this 
cohort (31/62) had less than 2 years of seizure free before AED withdrawal, and 
almost all patients who experience seizure relapse belong to this group (15/17). 
Cox regression models showed that having seizures in the last 2 years before 
AED withdrawal had nine times more risk of seizure relapse (HR 9.21 95%IC 
2.22-38.04 p= 0.002). Further analysis of only these participants (seizure-free ≤24 
months) found that having a history of ten or more seizure and at least one 
generalized seizure or focal seizure with generalization show a trend of increased 
risk of seizure relapse but without statistical significance. 
   
  






5.2 STUDY LIMITATIONS 
 
5.2.1 Study 1 
The main weaknesses of this study were the limitations inherent in the 
neuroimaging techniques and the loss to follow-up. MRI is the standard test for 
evaluating viable parenchymal cysts, and CT scan is the best technique to identify 
parenchymal calcified lesions.
37, 47, 49, 224
 However, the sensitivity and specificity 
of these neuroimaging techniques are suboptimal. Additionally some of the 
participants in the original trials may have been evaluated using different 
neuroimaging machines, and this may have introduced a measurement bias. 
However, since patients come from three randomized clinical studies, this is 
likely a non-differential bias and did not significantly alter the results observed in 
this study.  
 
Another limitation is the loss to follow-up.  However, the number lost to 
follow-up were minimal (8.5%, 18/212) and, due to the internal validation of the 
original studies, these losses were probably of a non-differential nature. 
 
5.2.2 Study 2 
The main study limitation of this study was a potential recall bias, due to 
long history of seizure among participants in this cohort. As a consequence, recall 
bias may have affected the numbers and type (description) of seizures 
documented at baseline.
225, 226
 Also in cases of generalized seizures we obtain the 
information from a close relative and/or witness who could only partially observe 
and describe the seizure episode. Thus information bias could have caused an 
underestimation of the number of events in the cohort.  
 
Additionally, the study team was not masked to the radiological or clinical 
information. Thus some conditions, such as many or large calcifications or history 





of severe or recurrent seizures may have resulted in an overestimate of the 
numbers of BTS. We included patients attending a national referral center for 
neurological diseases in Peru. Therefore they represent a selected proportion of 
subjects with NCC, and most likely those with suboptimal seizure control, and 
because of this, selection bias may have been introduced affecting the 
representativeness of the results. Those censored due to stopping AED may 
induce informative censoring. 
 
5.2.1 Study 3 
The main weakness of this cohort is the small numbers of participants 
which would affect the statistical significance and did not allow us to perform a 
multivariate model analysis. We did not perform an EEG before AED withdrawal 
because patient care was not part of the observational study. Additionally, we had 
no video-EEG support, in order to have a solid evidence of seizure 
characterization. As in the previous study, we included in this study patients who 
seeked medical care at the INCN (Instituto Nacional de Ciencias Neurologicas), a 
national referral center for neurological disease in Peru. In this sense, a lack of 
representativeness of the study population is anticipated. And, finally as in the 
parent cohort, seizure recall, the use of witnesses of the event as an indirect source 
of information, and the fact that the study physician was not masked to the 
radiological or clinical information and may be potential bias in our study. 
  






5.3 RECOMMENDATIONS FOR FUTURE RESEARCH  
 
5.3.1 Study 1 
There is strong evidence that brain calcifications are associated with 
epilepsy in NCC.
23, 121, 124
 Avoiding or reducing the calcification process could 
potentially reduce the risk of seizures in the long term. This cohort could serve to 
evaluate if a greater proportion of calcification is associated with more seizure 
relapse in the long term. Also we can evaluate serological status (number of 
reactive bands at EITB Western blot) decay over time and see if it correlates with 
the proportion of remaining calcified lesions or further seizure events. Our cohort 
presented with 38% calcified lesions at one year after antiparasitic treatment; we 
can take advantage of this cohort to explore if new calcified lesions appear in the 
following years as was suggested by Das and collaborators,
24
 which could mean 
that the process of calcification of each cyst follows a different time pattern in 
each individual.  
 
According to our findings, there are two additional interventions in 
patients with viable parenchymal NCC that could potentially reduce the risk of 
calcification: (1) the use of a higher-dose of corticosteroid regimen and (2) early 
re-treatment with antiparasitic drugs. These studies could initially be evaluated in 
animal models for further implementation in human studies. Additional 





 could also be evaluated. 
 
5.3.1 Study 2 
There is a lack of studies that explore the precipitating (trigger) factor(s) 
for breakthrough seizures in patients with calcified NCC. This has been 
extensively studied in causes of epilepsy but not in patients with calcified NCC 
under AED treatment. In order to provide evidence–based AED management to 





patients with calcified NCC, we would like to develop a prospective, controlled 
study comparing AED regimes. We were surprised to find that number or location 
of calcification was not related with BTS. This opens additional lines of research 
that should be explored such as genetic factor that can affect the epileptic 
threshold or biomolecular marker that are involved in seizure an epilepsy in this 
patients. Abnormal interictal EEG is a main biomarker for early BTS. Thus, 
studies in prolonged EEG and/or video EEG could be more informative predictors 
of BTS. With the results from larger, multicenter studies a tests and 
recommendations could be developed to help physicians provide better care for 
patients with epilepsy due to calcified NCC.
140
 Since calcified NCC is a chronic 
condition, it can serve as a model to evaluate structural and functional brain 
changes, such as the hippocampal sclerosis
16, 205
 or thinning of the cerebral cortex 
and its relationship with new convulsive events.
231, 232
    
 
5.3.1 Study 3 
Our findings support the recommendation that patients with calcified NCC 
and epilepsy should maintain their AED treatment until completion of at least 2 
years free of seizures. The estimated relapse rate in these patients is less than 10% 
(2/31) in the 3 years of follow up after AED withdrawal. Future studies should 
evaluate in patients with calcified NCC that already achieved at least 2 years free 
of seizures, if an extra year or 2 years of antiepileptic treatment really offers a 
significant decrease of seizure relapse in the following years, as suggested by 
many authors in epilepsy due to other causes than NCC.
145, 209, 210, 213, 214
 A larger 
cohort should be conducted to confirm potential risk factors such as having a 
history of ten or more seizure, having less than 36 months with seizures, and 
having had at least a generalized seizure or focal with generalization. Also 
abnormal electrical activity at EGG (extended tracing and/or video-EEG) should 
be evaluated as a risk factor before AED withdrawal.
148, 211, 212
. Also to explore 
precipitating (trigger) factor of seizure relapse in calcified NCC patients without 
AED treatment has not been still studied. Finally, as in the study 2, larger and 
multicentric studies can provide enough information to develop monogram that 





individualize the medical care and recommendation for people with epilepsy due 











5.4 POLICY IMPLICATIONS 
 
Our findings can impact directly the management of patients with calcified NCC. 
According to our results from study 1, use of combined antiparasitic drugs, albendazole 
plus praziquantel, results in fewer calcifications compared to increased doses of ABZ,
77, 
172, 173
  and use of enhanced doses of corticosteroids versus the standard doses during the 
antiparasitic treatment and weeks after
78
 not only improved the control for seizure in the 
first weeks of antiparasitic treatment, as demonstrated by Garcia and collaborators, but 
decreases the proportion of calcified cysts. Finally, we can recommend considering an 
early antiparasitic re-treatment regardless the efficacy of the initial antiparasitic course in 
order to reduce the proportion of calcification.  If these interventions reduce the 
proportion of calcified lesions we can possibly also reduce the subsequent burden of 
seizures due to NCC.  
 
Studies 2 and 3 are focused on patients with established NCC calcified lesions, 
who will remain with this condition for their entire life. Some of these patients will have 
recurrent, and in a few cases, intractable epilepsy. As a chronic condition there are some 
structural consequences such as hippocampal sclerosis or cortical thickness that can 
worsen their epilepsy.
16, 205, 231, 232
  
 
Seizures and epilepsy have an important impact in neurobiological, cognitive, 
psychosocial consequences, and economical aspects.
233
 Identifying and implementing 
interventions to reduce the calcification scars could potentially improve the prognosis the 
secondary epilepsy (Study 1). Also identifying risk factors for breakthrough seizures may 
improve antiepileptic care in patients with calcified NCC (Study 2). Finally, consistent 
criteria for AED withdrawal (Study 3) will not only reduce morbidity and mortality 
caused by this disease but will also improve the quality of life, reduce stigma and lower 
associated direct and indirect cost for patients and health systems.  
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A. Personal Statement 
My participation in the Cysticercosis Working Group in the last 18 years and the permanent 
training in research activities have been fruitful where I acted as associate investigator and 
responsible for design, monitoring and ethics and regulatory-related issues of clinical and pre-
clinical research studies. I have been member of the IRB of the US Naval Medical Research 
Center Detachment in Peru for three years. After of my medical degree I have completed two 
Master degrees, one in Infectious Diseases Control at Universidad Peruana Cayetano Heredia and 
the second one in Public Health at Johns Hopkins School of Public Health (JHSPH). Currently I 
am PhD candidate in the International Health department (Global Disease Epidemiology and 
Control program) at JHSPH. Also I am PI of a current NIH-IRID grant in animal models 
involving naturally infected pigs (1R01AI116456-01).  
 
B. Positions and Honors 
 
Positions and Employment 
2001 – Pres. Associate Investigator and Bioethics Officer, Cysticercosis Unit, 
Universidad Peruana Cayetano Heredia - Instituto Nacional de Ciencias 
Neurologicas, Lima, Peru. 





2014 – Pres. Associate Investigator at Center for Global Health, Universidad Peruana 
Cayetano Heredia, Lima, Peru. 
2016  – 2017 WHO, Diagnosis and Treatment Guidelines for Taenia solium 
Neurocysticercosis, Member of the Sistematic Review group.   
2008 – 2010 Chief Project Officer Caritas Ayaviri – Puno 
2006 – 2010  IRB Member, Naval Medical Research Center Detachment. Peru  
2001 – 2002  Attending Physician: Centro Medico “Sagrada Familia”, Lima Peru. 
2000 – 2001  Fellow in, Internal Medicine, Surgery, Pediatrics at Hospital Nacional 
Cayetano Heredia, Lima Peru and Gynecology at Hospital Arzobispo 
Loayza Lima, Peru.  
 
Award  
2012   Ruth Rice Puffer Fund Scholarship for International Students  
Johns Hopkins School of Public Health 
 
C. Contribution to Science 
 
1. Most of my contributions to science have been as part of the Cysticercosis Working 
Group. Probably the main contribution is related to the development of better 
antiparasitic treatment for patients with neurocysticercosis. As part of my medical degree 
dissertation, while still in medical school, I began working on research testing a short 
treatment for neurocysticercosis (Bustos 2006). After that, I collaborated with the idea to 
improve the treatment efficacy with a new approach: the combined antiparasitic treatment 
with albendazole plus praziquantel. I lead the pre-clinical studies in naturally infected 
pigs with promising results (Gonzalez 20012). These results were strong enough to get 
funds to develop two clinical trials; the first one to evaluate pharmacokinetics aspects 
(Garcia 2011) and the second one to evaluate the efficacy of the treatment in a 
multicentric clinical trial (Garcia 2014). The results have re-defined the standard of care 
of this disease.  
 
 Bustos JA, Pretell EJ, Llanos-Zavalaga F, Gilman RH, Del Brutto OH, 
Garcia HH; for The Cysticercosis Working Group in Peru. Efficacy of a 3-day 
course of albendazole treatment in patients with a single neurocysticercosis 
cyst. Clin Neurol Neurosurg. 2006 Feb;108(2):193-4. 
 Gonzalez AE, Bustos JA, Jimenez JA, Rodriguez ML, Gilman RH, Garcia 
HH; Cysticercosis Working Group in Peru. Efficacy of diverse antiparasitic 
treatments for cysticercosis in the pig model. Am J Trop Med Hyg. 2012 
Aug;87(2):292-6.  
 Garcia HH, Lescano AG, Lanchote VL, Pretell EJ, Gonzales I, Bustos JA, 
Takayanagui OM, Bonato PS, Horton J, Saavedra H; Pharmacokinetics of 
combined treatment with praziquantel and albendazole in neurocysticercosis. 
British Journal of Clinical Pharmacology; 2011;  72:77-84. PMCID 3141188 
 Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Gavidia M, 
Rodriguez L., Najar E., et al. Efficacy of combined antiparasitic therapy with 
praziquantel and albendazole for neurocysticercosis: a double-blind, 
randomised controlled trial. Lancet Infectious Diseases, 2014 Jul; 14:687-695.  
 
2. As part of my dissertation for a master program in Control of Infectious Diseases. I 
developed a study to evaluate the usefulness of a new ELISA test to detect antigens of a 
T.solium tapeworm  (CoAg-ELISA) after antiparasitic treatment.  The study provided 
evidence that CoAg-ELISA is useful to evaluate treatment failure in taeniasis. Early 





assessment at day 15 would detect treatment failure before patients become infective. 
This is an important piece of information for control program of taeniasis/cysticercosis.  
 
 Bustos JA, Rodriguez S, Jimenez JA, Moyano LM, Castillo Y, Ayvar V, 
Allan JC,  Craig PS, Gonzalez AE, Gilman RH, Tsang VC, Garcia HH; 
Cysticercosis Working Group in Peru. Detection of Taenia solium taeniasis 
coproantigen is an early indicator of treatment failure for taeniasis. Clin 
Vaccine Immunol. 2012 Apr;19(4):570-3. 
 
3. Calcified lesions are the most common cerebral finding of NCC because they accumulate 
in the brain and are a measure of prior infections. It is agreed that even after a successful 
anti-parasitic treatment, the remaining calcified scars persist, acting as foci of relapsing 
inflammation and seizures. I have participated in studies to characterize this phenomenon 
and currently I am conducting a study in animal models to evaluate the role of 
bisphosphonates as an option to avoid or reduce the calcification process and their 
consequences.  
 
 Bustos JA, Garcia HH, Dorregaray R, Naranjo M, Pretell EJ, Gonzalez AE, 
Gilman RH; for The Cysticercosis Working Group in Peru. Detection of 
muscle calcifications by thigh CT scan in neurocysticercosis patients. Trans R 
Soc Trop Med Hyg. 2005 Oct;99(10):775-9. 
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Residual brain calcifications in neurocysticercosis. Am J Trop Med Hyg. 
2008 Mar;78(3):363.  
 Nash TE, Pretell EJ, Lescano AG, Bustos JA, Gilman RH, Gonzalez AE, 
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and seizure activity in patients with calcified NCC: a prospective cohort and 
nested case-control study. Lancet Neurol. 2008 Dec;7(12):1099-105.  
 1R01AI116456-01, NIH-NIAID, (PI: Bustos, JA), 4/01/2015 - 03/31/2020, 
“Use of bisphosphonates to reduce the calcification process in animal models 
of cysticercosis” 
 
4. In a shared effort with Dr. Garcia and Katherine Sota, a UPCH medical student, we 
developed the idea of a new animal model for neurocysticercosis and epilepsy using 
sheep. With this proposal, Ms. Sota got a small intramural grant for the initial steps to 
evaluate the feasibility of experimental intracranial infection with oncospheres of T. 
solium. In 4 out of 15 sheep of 4 to 8 months of age. Direct microscopic observation and 
histological evaluation with H-E staining confirmed that the cyst corresponds to cyst or 
degenerating larval stage of T. solium. This exploratory experiment provided the proof-
of-concept that intracranial experimental infection with T. solium post-oncopheres could 
cause neurocysticercosis in the sheep model.  
 
5. WHO Consultant. In August 2016, I was asked to conduct systematic reviews for the 
drafting of “WHO Diagnosis and Treatment Guidelines for Taenia solium 
Neurocysticercosis (NCC)” and provided the report for consideration by the Guideline 
Review Committee.  These systematic reviews covered twelve PICO Questions. The 
guideline was targeted at health care providers working at a first or second level facility 
or at district level including basic outpatient and inpatient services. It was also aimed to 
be used by the policy makers, health care planners and program managers in government 





and development and international agencies. These guidelines will also be useful for 
academicians and researchers to inform teaching and research agendas. 
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F. Research Support 
Ongoing Research Support  
1R01AI116456-01   (BUSTOS, Javier A.)  March 2015 – Feb 2020    
NIAID-NIH 
Title: Use of bisphosphonates to reduce the calcification process in animal models of 
cysticercosis 
- The aim of the study is to standardize an experimental model of cysticercosis infection and 
calcification in animal model and use it to evaluate whether bisphosphonates can interrupt the 
process of residual calcification. 
Role: Principal Investigator 
 
1U01NS086974-01A1   (GARCIA, Hector H.)  Aug 2015 – Jul 2020  
NINDS-NIH 
Title: Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application 
- Clinical trial to evaluate whether the addition of PZQ during the initial 15 days of treatment of 





SANCC improves the efficacy of the standard of care ABZ regimen in terms of a higher 
proportion of patients demonstrating disappearance of their SANCC lesions as well as an 
increased percent reduction of parasite volume.  
Role: Medical Monitor  
 
2D43TW001140-16   (GARCIA, Hector H.)          Jul 2016 – Jun 2021               
FIC – NIH 
Title: Training in Infectious Diseases in Peru – Time for Capacity Strengthening in Clinical 
Research 
- The program will enroll 50 medium-term mentored post-graduate and pre-graduate students in a 
Diploma course (10 per year), 25 mentored Master's degree students (five per year), and up to 
seven PhD students including four enrolled in the UPCH PhD program.  
Role: Collaborator  
 
U19AI129909    (GARCIA, Hector H.)              Apr 2017 – Mar 2022                     
Title: Improving Diagnostic and Management Tools for NCC  (Peru-JHU TMRC Program) 
- Program grant to develop improved tools in key required areas for the diagnosis or monitoring 
of human cysticercosis 
Role: Investigator 
 
1R01NS103623-01A1   (O'NEAL, Seth E.)      Jul 2018 – Jun 2023 
Title: Urine Screening for early detection of subarachnoid Neurocysticercosis   
- This proposal evaluates urine screening for early detection of the most severe form 
of infection in order to improve clinical outcomes. 
Role: Medical Monitor 
 
1R01AI143553-01   (ARROYO, Gianfranco) Mar/2019 – Feb/2023   
NIAID- NIH       
Title: Alternative therapeutic approaches for the control of brain inflammation secondary to 
anthelmintic therapy in neurocysticercosis using a novel experimental pig model 
- This proposal aims to optimize a novel experimental pig model for NCC, and to use this 
model to assess alternative therapy approaches using two drugs: etanercept and methotrexate 
as potential corticosteroid-sparing/replacing drugs for use in NCC. 
Role: Co-Investigator  
 
Completed Research Support  
R21 NS094976-01       (GARCIA, Hector H.)      Jul 2016 – Dec 2017            
NIH-NINDS        
“Characterization of hippocampal sclerosis in individuals with calcified neurocysticercosis” 
This project will explore hippocampal compromise in individuals with resolved 
neurocysticercosis to assess the relationship between NCC and hippocampal atrophy 
Role: Medical Monitor 
 
Grant 23981   Cysticercosis Working Group in Peru   April 2003 to 2014 
Bill and Melind a Gates Foundation    
A Demonstration Project to Eliminate Cysticercosis in Peru 
Seven-years project to demonstrate feasibility of elimination in a defined endemic area 
Role: Medical Monitor 
 
RO1 NS054805 01                 (GARCIA, Hector H.)    04/01/2006 - 2013 





NINDS – NIH 
Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of 
Combined Treatment with Praziquantel and Albendazole. To determinate if a 10-day 
combined regime of PZQ and ABZ improves the parasiticidal efficacy of ABZ alone at the 
same dose. 
Role: Medical Monitor & Bioethics Assurance Officer  
 
05-I-N124   Theodore Nash (PI)                2005 – 2010 
NIAID- NIH (intramural research) 
Increased Dosing of Corticosteroids in the Treatment of Intraparenchymal 
Neurocysticercosis 
Role: Medical Monitor & Bioethics Assurance Officer  
 
 
 
 
 
